Principia Biopharma, Inc.  1 of 100 
Confidential and Proprietary   01-Mar -2022  Final
AMENDED CLINICAL TRI AL PROTOCOL 02   
Protocol Title:  A randomized, intra -patient, double -blind, 
placebo -controlled study to evaluate the safety, 
tolerability, and pharmacokinetics of topically 
administered PRN473 (SAR444727) in patients with 
mild to moderate  atopic dermatitis  
Protocol Number:  PRN473 -0005 (ACT17131)  
Amendment Number:  Amendment 02  
Compound number 
(INN/Trademark):  PRN473 (SAR444727)  
Not applicable  
Brief Title:  Phase 2a study of the safety, tolerability, 
and pharmacokinetics of topically administered 
PRN473 (SAR444727)  in patients with mild to 
moderate atopic dermatitis  
Study Phase:  2a 
Sponsor Name:  Principia Biopharma, Inc.  
Legal Registered Address:  220 E. Grand Avenue  
South San Francisco, CA 94080  
USA  
Sponsor’s Medical Contact:  
Monitoring team’s 
representative name and 
contact information  
Regulatory agency identifier number(s):  
IND Number:  152941  
EudraCT:  Not applicable  
NCT:  [STUDY_ID_REMOVED]  
WHO:  Not applicable  
EUDAMED  Not applicable  
Other:  Not applicable  
Approval Date:  01-Mar-2022 Final
Confidentiality Statement  
This document contains confidential information of Principia Biopharma, Inc. It is provided for 
the sole use of the Principal Investigator, sub -investigators, staff, institutional review boards, 
human research ethics committees, and regulatory authorities. By accepting this document, you 
agree to maintain the information as confidential and to use it only for the purpose of 
conducting or reviewing the study protocol.  
VV-CLIN-0613618 3.0

Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  2 of 100 
Confidential and Proprietary   01-Mar -2022  Final  PROTOCOL AMENDMENT S UMMARY OF CHANGES   
DOCUMENT HISTORY  
 
Document  Country/countries 
impacted by amendment  Date, version  
Amended Clinical Trial Protocol 02  global  01 March 2022, version 1 (electronic  3.0) 
Amend ed Clinical Trial Protocol 01  global  15 June 2021, version 1 (electronic 2.0)  
Original Protocol   19 March 2021, version 1 (electronic 2.0)  
Amendment 02 ( 01 March  2022 ) 
OVERALL RATIONALE FOR THE AMENDMENT  
This protocol is being amended to provide more flexibility to allow the investigational product to 
be administered at home or external clinic during Blinded Period, update statistical interim 
analysis to facilitate the internal decision making and to make other clarifications deemed 
necessary by the Sponsor.  
Protocol amendment summary of changes table  
Section # and Name  Description of Change  Brief Rationale  
Title Page  Updated the study Sponsor’s Medical 
Contact and study NCT numbers. 
Updated protocol version and date.  Administrative.  
Protocol amendment summary of changes 
table  Included the overall rationale and 
protocol amendment summary of 
changes table for current amendment.  Administrative.  
Section 1.1 synopsis; Section 3 objectives 
and endpoints; Section 8.6 Biomarkers  Included the RNA expression analysis in 
biomarker assessments.  To determine the effect of IMP on 
lesional transcriptional profile and 
its associated mechanisms on skin 
inflammation and barrier function.  
Section 1.1 synopsis; Sectio n 4.1 overall 
design; Section 6.2 
Preparation/handling/storage/accountability   Added “ The investigational products will 
be applied at the study site, at the 
patient’s home, or at an external clinic, 
where available.”  To provide flexibility to allow IMP 
administration at home by trained 
medical professional  or external 
clinic during Blinded Period.  
Section 1.1 synopsis; Section 4.1 overall 
design  Specified the STS assessment to be 
performed predose on Days 1, 8 
(optional), 15, 29, and at Day 43 for the 
target lesions . For clarity.  
Section 1.1 synopsis; Section 9 .5 interim 
analysis ; Section 6.3  measures to minimize 
bias: randomization and blinding  Updated the language on interim 
analysis . To facilitate internal decision 
making.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  3 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Section # and Name  Description of Change  Brief Rationale  
Throughout  Adjusted the term of “at clinic” to “at study 
site”, where applicable.  To distinguish from “external clinic” 
and to align the term throughout.  
Included a trained medical professional in 
addition to site staff, where applicable, 
considering that IMP might be applied at 
home or external clinic.  To provide flexibility to allow IMP 
administration at home by trained 
medical professional or at external 
clinic during Blinded Period.  
Section 1.2 schema  Updated the panel for blinded period by 
adding “at home or external clinic” .   To provide flexibility to allow IMP 
administration at home by trained 
medical professional or at external 
clinic during Blinded Period.  
Section 1.2 schema, Section 1.3 schedule 
of activities  Updated footnote “a” by adding “The 
investigational products could be applied 
by a trained medical professional at 
patient’s home or an external clinic, 
where available, as a backup option.”  To provide flexibility to allow IMP 
administration at home by trained 
medical professional or at external 
clinic during Blinded Period.  
Section 1.3 schedule of activities  Updated the header for blinded period 
from “in -clinic” to “at study 
site/home/external clinic” . To provide flexibility to allow IMP 
administration at home by trained 
medical professional or at external 
clinic during Blinded Period.  Updated the footnote “t” and introduced a 
new footnote “u” to include study 
intervention dosing during blinded period 
visits to be applied  at study site, at home 
or an external clinic , where available.  
Added annotation  “b” to PP -NRS 
assessment and photograph s at D15  and 
D29 visit. To clarify that the PP -NRS and 
photography will be performed 
predose.  
Added study intervention dosing at D29 
visit and included annotation “n” . To correct an omission . 
Footnote "n" was modified to clarify that 
the dosing at D29 visit to be done after 
predose assessments at study site.  For clarity . 
Footnote "q" was modified to clarify that 
the STS assessment to be performed 
predose.  Added annotation “b” to STS 
assessment at D15 and D29 visit.  For clarity . 
Section 1.3 schedule of activities; Section 
8.9 lesion photography  Corrected the D15 visit from Blinded 
Period to Open -Label Period in SoA table 
footnote “l” and in Section 8.9.  To correct an error.  
Specified the photographs to be taken of 
the 2 target lesions predose at Baseline, 
D8, D15, D29 and at D43.  For clarity.   
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  4 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Section # and Name  Description of Change  Brief Rationale  
Section 6.2 preparation/handling/storage/ 
accountability  Defined the “study staff” who may supply 
or administer IMP during the Blinded 
Period . For clarity . 
 Clarified that t he Investigator or designee 
is responsible for the education of “site 
staff” rather than “study staff” . For clarity . 
 Included text on specifying the condition 
when IMP application at home or external 
became applicable.   To provide flexibility to allow IMP 
administration at home by trained 
medical professional or at external 
clinic during Blinded Period.  
Section 6.3 measures to minimize bias  
randomization and blinding  Clarified that the local tolerability 
assessment to be performed by another 
trained medical professional different 
than the person administering the study 
intervention , if the investigational 
products are applied at the patient’s 
home or at an external clinic . Measures taken for minimize the 
bias.  
Section 6.4 study intervention compliance  Clarified the trained medical professional, 
in addition to site staff, was responsible 
for study intervention administration and 
study conduct.  For clarity . 
Section 7.1.1 permanent discontinuation  Added ALT >5 × ULN in the listing of 
events leading to pe rmanent IMP 
discontinuation .  To correct an omission and align 
with decision chart in Section 10.3.  
Section 9.4.4.5 laboratory data  Replaced the term 'vital signs' with 
'laboratory data'.  To correct the error.  
Section 10.5 appendix 5: Protocol 
Amendment History  Added the overall rationale and protocol 
amendment summary of changes table 
for amendment 01 . To include the document history.  
Throughout document  Other minor editorial changes 
(eg, grammatical, stylistic, and minor 
typographical error corrections ). Minor, therefore, have not been 
summarized . 
   
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  5 of 100 
Confidential and Proprietary   01-Mar -2022  Final   
TABLE  OF CONTENTS  
AMENDED CLINICAL TRI AL PROTOCOL 02  ................................ ................................ ..... 1 
PROTOCOL AMENDMENT S UMMARY OF CHANGES  ................................ ....................  2 
TABLE OF CONTENTS  ................................ ................................ ................................ ..............  5 
LIST OF TABLES  ................................ ................................ ................................ .........................  9 
LIST OF ABBREVIATION S ................................ ................................ ................................ ..... 10 
1 PROTOCOL SUMMARY  ................................ ................................ ..............................  13 
1.1 SYNOPSIS  ................................ ................................ ................................ ............  13 
1.2 SCHEMA  ................................ ................................ ................................ ..............  21 
1.3 SCHEDULE OF ACTIVITI ES (SOA ) ................................ ................................ . 22 
2 INTRODUCTION  ................................ ................................ ................................ ...........  26 
2.1 STUDY RATIONALE  ................................ ................................ ..........................  26 
2.2 BACKGROUND  ................................ ................................ ................................ ... 28 
2.2.1  Nonclinical studies ................................ ................................ ................  28 
2.2.1.1  Nonclinical pharmacology ................................ .............................  28 
2.2.1.2  Pharmacokinetics and metabolism in animals  ...............................  31 
2.2.1.3  Nonclinical toxicology  ................................ ................................ .. 32 
2.2.2  Clinical studies ................................ ................................ ......................  33 
2.3 BENEFIT/RISK ASSESSM ENT  ................................ ................................ ..........  34 
2.3.1  Risk assessment  ................................ ................................ ....................  34 
2.3.2  Benefit assessment  ................................ ................................ ................  34 
2.3.3  Overall benefit/Risk assessment  ................................ ...........................  34 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ ................  35 
4 STUD Y DESIGN  ................................ ................................ ................................ .............  37 
4.1 OVERALL DESIGN  ................................ ................................ .............................  37 
4.2 SCIENTIFIC  RATIONALE FOR STUDY  DESIGN  ................................ ...........  38 
4.3 JUSTIFICATION FOR DO SE ................................ ................................ ..............  39 
4.4 END OF STUDY DEFINIT ION ................................ ................................ ...........  40 
5 STUDY POPULATION  ................................ ................................ ................................ .. 41 
5.1 INCLUSION CRITERIA  ................................ ................................ ......................  41 
5.2 EXCLUSION CRITERIA  ................................ ................................ .....................  42 
5.3 LIFESTYLE CONSIDERAT IONS ................................ ................................ ....... 45 
5.3.1  Meals and dietary restrictions  ................................ ...............................  45 
5.3.2  Caffeine, alcohol, and tobacco ................................ ..............................  45 
5.3.3  Activity  ................................ ................................ ................................ . 45 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  6 of 100 
Confidential and Proprietary   01-Mar -2022  Final  5.4 SCREEN FAILURES  ................................ ................................ ............................  45 
5.5 CRITERIA FOR TEMPORA RILY DELAYING ADMINI STRATION OF 
STUDY INTERVENTION  ................................ ................................ ...................  45 
6 STUDY INTERVENTION A ND CONCOMITANT THERA PY ...............................  46 
6.1 STUDY INTERVENTION ( S) ADMINISTERED  ................................ ..............  46 
6.2 PREPARATION/HANDLING /STORAGE/ACCOUNTABIL ITY .....................  46 
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLI NDING  ... 48 
6.4 STUDY INTERVENTION C OMPLIANCE  ................................ ........................  50 
6.5 DOSE MODIFICATION  ................................ ................................ ......................  50 
6.6 CONTINUED ACCESS TO STUDY INTERVENTION A FTER THE END 
OF STUDY  ................................ ................................ ................................ ............  50 
6.7 CONCOMITANT THERAPY  ................................ ................................ ..............  50 
6.7.1  COVID -19 vaccination  ................................ ................................ .........  51 
6.7.2  Prohibited medications  ................................ ................................ .........  51 
6.7.3  Permitted medications  ................................ ................................ ..........  52 
6.7.4  Rescue medicine  ................................ ................................ ...................  52 
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PATIENT 
WITHDRAWAL ................................ ................................ ................................ ..............  53 
7.1 DISCONTINUATION OF S TUDY INTERVENTION  ................................ ....... 53 
7.1.1  Permanent discontinuation ................................ ................................ .... 53 
7.1.2  Liver chemistry stopping criteria  ................................ ..........................  54 
7.1.3  QTc stopping criteria  ................................ ................................ ............  54 
7.1.4  Hematology stopping criteria  ................................ ...............................  54 
7.2 PATIENT DISCONTINUAT ION/WITHDRAWAL FROM THE STUDY  ........  54 
7.3 LOST TO FOLLOW -UP ................................ ................................ .......................  55 
8 STUDY ASSESSMENTS AND PROC EDURES  ................................ ..........................  56 
8.1 EFFICACY ASSESSMENTS  ................................ ................................ ...............  56 
8.2 SAFETY ASSESSMENTS  ................................ ................................ ...................  57 
8.2.1  Phys ical examinations  ................................ ................................ ..........  57 
8.2.2  Vital signs  ................................ ................................ .............................  57 
8.2.3  Electrocardiograms  ................................ ................................ ...............  58 
8.2.4  Clinical safety laboratory assessments  ................................ .................  58 
8.2.4.1  Clinical laboratory tests  ................................ ................................ . 59 
8.2.5  Pregnancy testing  ................................ ................................ ..................  60 
8.2.6  Local Cutaneous Tolerability  ................................ ...............................  60 
8.3 ADVERSE EVENTS, SERI OUS ADVERSE EVENTS A ND OTHER 
SAFETY REPORTING ................................ ................................ .........................  60 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  7 of 100 
Confidential and Proprietary   01-Mar -2022  Final  8.3.1  AEs and SAEs: Definitions and procedures for recordi ng, evaluating, 
follow -up, and reporting  ................................ ................................ ....... 61 
8.3.1.1  Definition of AE  ................................ ................................ ............  61 
8.3.1.2  Definition of SAE  ................................ ................................ ..........  62 
8.3.1.3  Recording and follow -up of AE and/or SAE  ................................  63 
8.3.1.4  Reporting of SAEs  ................................ ................................ .........  65 
8.3.2  Time period and frequency for collecting AE and SAE information  ... 66 
8.3.3  Method of detecting AEs and SAEs  ................................ .....................  66 
8.3.4  Follow -up of AEs and SAEs ................................ ................................ . 66 
8.3.5  Regulatory reporting requirements for SAEs  ................................ ....... 66 
8.3.6  Pregnancy  ................................ ................................ .............................  67 
8.3.7  Expedited reporting requirements ................................ .........................  67 
8.3.8  Guidelines for reporting product complaints  ................................ ........  68 
8.4 PHARMACOKINETICS  ................................ ................................ ......................  68 
8.5 GENETICS AND/OR PHAR MACOGENOMICS  ................................ ...............  69 
8.6 BIOMARKERS  ................................ ................................ ................................ ..... 69 
8.7 IMMUNOGENICITY ASSES SMENTS  ................................ ..............................  70 
8.8 HEALTH ECONOMICS OR MEDICAL RESOURCE UTI LIZATION AND 
HEALTH ECONOMICS ................................ ................................ .......................  70 
8.9 LESION PHOTOGRAPHY  ................................ ................................ ..................  70 
9 STATISTICAL CONSIDER ATIONS  ................................ ................................ ...........  71 
9.1 STATISTICAL HYPOTHES ES ................................ ................................ ...........  71 
9.2 SAMPLE SIZE DETERMIN ATION  ................................ ................................ .... 71 
9.3 ANALYSIS SETS  ................................ ................................ ................................ . 71 
9.4 STATISTICAL ANALYSES  ................................ ................................ ................  72 
9.4.1  General considerations ................................ ................................ ..........  72 
9.4.2 Endpoints  ................................ ................................ ..............................  72 
9.4.3  Analysis of efficacy data  ................................ ................................ ...... 72 
9.4.3.1  Lesion Total Sign Score (TSS)  ................................ ......................  72 
9.4.3.2  Further efficacy endpoints during the blinded period  ...................  73 
9.4.3.3  Eczema Area and Skin Severity Index (EASI)  ..............................  73 
9.4.3.4  Validated Investigator Global Assessment -Atopic Dermatitis 
(vIGA -AD) ................................ ................................ ....................  74 
9.4.3.5  Further efficacy endpoints during the open -label period  ..............  74 
9.4.4  Analysis of safety data  ................................ ................................ ..........  74 
9.4.4.1 Assignment to treatment and study phase  ................................ ..... 75 
9.4.4.2  Analyses of adverse events  ................................ ............................  76 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  8 of 100 
Confidential and Proprietary   01-Mar -2022  Final  9.4.4.3  Local cutaneous tolerability  ................................ ..........................  76 
9.4.4.4  Extent of study treatment exposure and compliance  .....................  76 
9.4.4.5  Laboratory data  ................................ ................................ ..............  77 
9.4.4.6  Vital signs  ................................ ................................ ......................  77 
9.4.4.7  Electrocardiogram  ................................ ................................ .........  77 
9.4.5  Analysis of pharmacokinetic data  ................................ .........................  77 
9.4.5.1  Pharmacokinetic parameters  ................................ ..........................  77 
9.4.5.2  Analysis of pharmacokinetic concentrations  ................................ . 77 
9.4.6  Other analyses  ................................ ................................ .......................  78 
9.4.6.1  Biomarkers  ................................ ................................ ....................  78 
9.4.6.2  Furthe r exploratory endpoint(s)  ................................ .....................  78 
9.5 INTERIM ANALYSIS  ................................ ................................ ..........................  78 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ....... 79 
10.1  APPENDIX 1: REGULATO RY, ETHICAL, AND STU DY OVERSIGHT 
CONSIDERATIONS  ................................ ................................ ............................  79 
10.1.1  Regulatory and ethical considerations  ................................ ..................  79 
10.1.2  Financial disclosure  ................................ ................................ ..............  79 
10.1.3  Informed consent process  ................................ ................................ ..... 80 
10.1.4  Data protection ................................ ................................ ......................  80 
10.1.5  Data quality assurance  ................................ ................................ ..........  80 
10.1.6  Source documents  ................................ ................................ .................  81 
10.1.7  Study and site start and closure  ................................ ............................  82 
10.1.7.1  Trial Stopping Rules  ................................ ................................ ...... 82 
10.1.7.2  Study/Site termination  ................................ ................................ ... 82 
10.1.8  Publication policy  ................................ ................................ .................  83 
10.2  APPENDIX 2: CONTRACEPTIVE AND BARRIER GUIDANCE  ...................  83 
10.2.1  Definition  ................................ ................................ ..............................  83 
10.2.2  Contraception guidance  ................................ ................................ ........  84 
10.2.3  Collection of pregnancy information  ................................ ....................  86 
10.3  APPENDIX 3: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS 
AND FOLLOW UP ASSESSMENTS AND STUDY INTERVENTION 
RECHALLENGE GUIDELINES  ................................ ................................ .........  87 
10.4  APPENDIX 4: ADDITIONAL APPENDICES  ................................ ....................  90 
10.4.1  Grading of application site tolerability symptoms ................................  90 
10.4.2  Validated investigator global assessment -atopic dermatitis 
(vIGA -AD) ................................ ................................ ...........................  91 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  9 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10.4.3  Lesion Total Sign Score (TSS)  ................................ .............................  92 
10.4.4  Hanifin and r ajka criteria  ................................ ................................ ...... 92 
10.5  APPENDIX 5: PROTOCOL AMENDMENT HISTORY  ................................ .... 93 
11 REFERENCES  ................................ ................................ ................................ ................  99 
 
LIST OF TABLES   
Table  1 - Summary of biochemical and cellular characterization of PRN473  ..............................  30 
Table  2 - Summary of PRN473 clinical studies  ................................ ................................ ............  33 
Table  3 - Objectives and endpoints  ................................ ................................ ...............................  35 
Table  4 - Study intervention  ................................ ................................ ................................ ..........  46 
Table  5 - Excluded medications and treatments  ................................ ................................ ............  51 
Table  6 - Laboratory tests  ................................ ................................ ................................ ..............  59 
Table  7 - Analysis sets  ................................ ................................ ................................ ...................  71 
Table  8 - Safety analysis ................................ ................................ ................................ ................  75 
 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  10 of 100 
Confidential and Proprietary   01-Mar -2022  Final  LIST OF ABBREVIATIONS   
Abbreviation or 
Specialist Term  Explanation  
AD atopic dermatitis  
AE adverse event  
ALT  alanine aminotransferase  
API active pharmaceutical ingredient  
ATP  adenosine triphosphate  
AUC  area under the concentration -time curve  
AUC 0-∞ area under the plasma concentration -time curve from zero to infinity  
AUC 0-last area under the plasma concentration -time curve from zero to the last 
measurable concentration  
BCR  B cell receptor  
BID twice daily  
BLQ  below the limit of quantification  
BSA  body surface area  
BTK  Bruton’s tyrosine kinase  
CI confidence interval  
CIOMS  Council for International Organizations of Medical Sciences  
CL int intrinsic clearance  
Cmax maximum plasma concentration  
COVID -19 coronavirus disease 2019  
CV%  percent coefficient of variation  
DLQI  Dermatology Life Quality Index  
DTP  direct to patient  
EASI  Eczema Area and Skin Severity Index  
ECG  electrocardiogram  
eCRF  electronic case report form  
EGFR  epidermal growth factor receptor  
FcR Fc-gamma receptor  
FcR Fc-epsilon receptor  
FDA  Food and Drug Administration  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  11 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Abbreviation or 
Specialist Term  Explanation  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
geometric CV%  geometric coefficient of variation  
IC50 half maximum inhibitory concentration  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
IGA Investigator Global Assessment  
IgE immunoglobulin E  
IgG immunoglobulin G  
IL interleukin  
IMP investigational medicinal product  
IRB Institutional Review Board  
IRT interactive response technology  
IUD intrauterine device  
IUS intrauterine system  
IV intravenous  
IWRS  interactive web response system  
NIMP  non investigational medicinal product  
NOAEL  no-observed -adverse -effect level  
OD optical density  
OTC  over-the-counter  
PCSA  potentially clinically significant abnormality  
PK pharmacokinetic  
PO per oral  
POEM  Patient -Oriented Eczema Measure  
PP-NRS  Peak Pruritus Numeric Rating Scale  
QD once daily  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.  12 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Abbreviation or 
Specialist Term  Explanation  
SCORAD  SCORing atopic dermatitis  
SD standard deviation  
STS skin tape stripping  
SUSAR  suspected unexpected serious adverse reaction  
TCI topical calcineurin inhibitor  
TSS total sign  score  
ULN  upper limit of normal  
UV ultraviolet  
vIGA -AD validated Investigator Global Assessment -Atopic Dermatitis  
WHO  World Health Organization  
 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   13 of 100 
Confidential and Proprietary   01-Mar -2022  Final  1 PROTOCOL SUMMARY   
1.1 SYNOPSIS   
Protocol Title:  A randomized, intra -patient, double -blind, placebo -controlled study to  evaluate 
the safety, tolerability, and pharmacokinetics of topically administered PRN473 
(SAR444727)  in patients with mild to moderate  atopic dermatitis  
Brief Title:  Phase 2a study of the safety, tolerability, and  pharmacokinetics of topically 
administered PRN473 (SAR444727)  in patients with mild to moderate atopic 
dermatitis  
Rationale:  PRN473 (also known as SAR444727) , a selective Bruton’s tyrosine kinase (BTK) 
inhibitor, is an  investigational drug being developed as a topical agent f or the 
treatment of  immune -mediated dermatological diseases. This study will explore 
the safety, tolerability, and plasma pharmacokinetics (PK) of topically 
administered PRN473 in  patients with mild to moderate atopic dermatitis (AD).  
Objectives and Endpoi nts: 
 
Objectives  Endpoints  
Primary   
Safety:  
To assess the safety and tolerability of PRN473 Gel, 
5% versus placebo administered twice daily (BID) up to 
6 weeks in patients with mild to moderate atopic 
dermatitis (AD)  Safety:  
• Incidence and severity of adverse events (AEs)  
• Changes in vital signs, electrocardiograms (ECGs), 
and laboratory tests 
• Assessment of local cutaneous tolerability 
assessment: incidence and severity 
of application -site events such as burning/stinging, 
itching, and erythema  
Secondar y  
PK: To evaluate the plasma PK of PRN473 following 
administration of multiple topical doses of PRN473 
Gel, 5% for 42  days in patients with mild to moderate 
AD • PK: Plasma  PRN473 concentrations at specified 
timepoints  
Exploratory  
• Biomarker: To evaluate  blood and skin changes in 
protein and RNA expression, lymphocyte  
infiltration, and epidermal thickness following 
treatment with PRN473 Gel, 5% at Days  8 and 15  • Biomarker: Change from Baseline in biomarkers 
using blood samples, skin tape stripping, and  skin 
biopsy  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   14 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Objectives  Endpoints  
• Efficacy: To evaluate the preliminary efficacy 
following double -blind treatment  with PRN473 
Gel, 5% compared to placebo at Days 8 and 15  Efficacy During Blinded Period:  
• Change  from  Baseline in lesion total sign score 
(TSS) at Days 8 and 15  
• Change  from Baseline in daily lesional Peak 
Pruritus Numeric Rating Scale (PP -NRS) score up 
to Day 15  
• Change from Baseline in lesional validated 
Investigator  Global Assessment (IGA) score at 
Days  8 and 15  
 • Lesion validated IGA response (proportion of 
patients with an IGA score of 0 or 1 and ≥2-grade 
improvement from Baseline) at Days 8 and 15  
• Efficacy: To evaluate the preliminary efficacy 
following open -label treatment with PRN473 Gel, 
5% at Days  29 and 43  Efficacy During Open -Label Period  
• Change from Baseline  in TSS for the 2 target 
lesions at Days 29 and 43.  
• Change from Baseline in Eczema Area and  Skin 
Severity Index (EASI) at Days 29 and 43  
• Change from Day 15 in EASI to Days 29 and  43 
• Proportion of patients with EASI 50, EASI 75, 
and EASI  90 from Day 15 to D ays 29 and 43  
• Change in PP -NRS from Day 15 to Days 29 and 43  
• Proportion of patients achieving at least 3 -point 
reduction from Day 15 in PP -NRS at Days 29 
and 43 
• Proportion of patients achieving at least a 4 -point 
reduction from Day 15 in PP -NRS at Days 29 
and 43 
• Change from Day 15 in weekly mean of PP -NRS at 
Days 29 and  43 
• Proportion of patients achieving at least 2 grade 
reduction  in vIGA -AD to clear (vIGA -AD 0) 
or almost clear (vIGA -AD 1) from Day 15 to 
Days  29 and 43  
• Change from Day 15 in SCORing atopic dermatitis 
(SCORAD) at Days 29 and 43  
• Change from Day 15 in percentage of treatable 
body surface area (BSA) at Days 29 and 43  
• Change from Baseline in Patient -Oriented Eczema 
measure (POEM) at Days 15, 29, and 43  
• Change from  Baseline in Dermatology Life Quality 
Index (DLQI) at Days 15, 29, and 43  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   15 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Overall Design:  
This is a Ph2a study that consists of a double -blind, intra -patient placebo -controlled treatment 
period and an open -label uncontrolled treatment period with objective to evaluate the safety, 
tolerability, PK and preliminary efficacy of PRN473 in up to 40 patients with mild to moderate 
AD. All patients are required to apply an emollient (except urea -containing or medicated 
emollients that are regulated as medical device) daily from Day -7 to Da y 1 (see  Section  6.2). On 
Day 1 (Baseline) of the Blinded Period, 2 target lesions with a difference no greater than 1  point 
in TSS w ill be randomly assigned to treatment in an intra -patient 1:1  manner, one lesion to 
PRN473 Gel, 5%, and the other to matching placebo. PRN473 Gel, 5%  and matching placebo are 
weighed and  applied twice daily (BID; morning and evening) at a  quantity of appro ximately 
2.5 mg/cm2 to a 100 cm2 area of each target lesion on Days  1-14 (Blinded Period). The 
investigational products will be applied at the study site, at the patient’s home , or at an external 
clinic, where available.   
During the Blinded Period, if the  target lesion is less than 100 cm2, the application area should 
include surrounding nonlesional skin (note: two target lesion skin biopsy specimens on Days 1 
and 15 are only on lesional skin); if the target lesion is larger than 100 cm2, only 100 cm2 of the 
lesion should be marked and treated. On  Days 15 -42 (Open Label Period), patients are instructed 
to apply PRN473 Gel, 5% BID to all AD -affected areas in a thin layer (excluding the scalp, 
palms, soles, and genitals) and should continue to treat the assig ned areas throughout the Open 
Label Period.  
Safety assessments include application site tolerability assessments (Appendix 4, Section  10.4.1 ), 
vital signs, ECGs, physical examination, safety labs, and AEs.  
To evaluate the PK (plasma concentrations) and biomarkers of PRN473, blood samples will be 
collected at study visits accordingl y to the SoA ( Section  1.3).  
Efficacy assessments of:  
• The lesional PP -NRS will be administered daily predose during th e Blinded Period 
(Days  1-14) and at predose Day 15.  
• The lesional validated IGA will be performed predose at Baseline (Day 1), Days 8, and 15.  
• The lesion TSS ( Appendix 4, Section  10.4.3 ) will be performed predose at Baseline 
(Day  1), Days 8, 15, and 29, and  at End of Study/Early Termination visit (Day  43). 
• The EASI, the POEM, and  the DLQI will be performed predose at Base line (Day 1), 
Days  15 and 29, and  at End of Study/Early Termination visit (Day  43). 
• The vIGA -AD ( Appendix 4, Section  10.4.2 ) will be performed at Screening, predose at 
Days 15 and 29, and  at End of Study/Early Termination visit (Day  43).  
• The SCORAD will be performed predose at Days 15 and 29, and  at End of Study/E arly 
Termination visit (Day  43). 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   16 of 100 
Confidential and Proprietary   01-Mar -2022  Final  • The PP -NRS will be administered daily predose before patient morning application during 
the Open -Label Period (Days 15 -42) and at  End of Study/Early Termination visit 
(Day  43).  
• The percentage of treatable BSA will be calculated at Screening, Days 15 and  29, and 
at End of Study/Early Termination visit (Day  43). 
To be included in the population analyzed for efficacy, the patient must have received at least 
80% of prescribed study intervention in the Blinded Period and/or  at least 80% of prescribed 
study intervention in the Open -Label Period.  
Skin tape stripping (STS) will be performed predose on Days 1, 8 (optional), 15, 29, and at 
Day 43 for the two target lesions, and on Day 1 for the normal skin. For a minimum of 20 pa tients 
(may be reduced to 15  patients if there is an impact on enrollment from coronavirus disease 2019 
[COVID -19]), a  4 or 5 mm punch skin biopsy will be collected from each target lesion on Days  1, 
15, and 29 (optional) and from normal skin on Day 1. The  lesional biopsy specimens at Days 15 
and 29 will be collected in  the vicinity of the Day  1 (Baseline lesional sample) biopsy but must be 
at least 1  cm away from the prior biopsy site. If the target lesion cleared after Day 1 and before 
Day 15, the biopsy specimen will be taken from the lesional skin location of the target area 
identified at Baseline.  
Additional information regarding study assessments and their timing is located in the Schedule of 
Activities ( Section  1.3). 
Study Duration:  
Participation will take approximately 13 weeks, including up to a 5 -week screening period, 
a 6-week treatment period, end of study assessments 1 day after last dose, and a safety follow -up 
phone call 2 weeks after last dose.  
Number of Patients:  
Up to 40 patients with mild to moderate AD are planned to be enrolled.  
Investigational Product  
PRN473 Gel, 5% (w/w) and placebo to match.  
Study Population:  
Inclusion Criteria  
Patients are eligible to be included in the study only if all the following criteria are met:  
1. Male and female adults 18 to 70 years of age (inclusive) at the time of  informed consent.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   17 of 100 
Confidential and Proprietary   01-Mar -2022  Final  2. Diagnosed with mild to moderate AD, m eeting at least 3 major and  3 minor criteria 
according to Hanifin and Rajka ( Hanifin  1980 ; Appendix  4, Section  10.4.4 ) prior to or at 
the Screening visit.  
3. History of AD for at least 6 months as determined by the Investigator through patient 
interview.  
4. Stable disease for the 4 weeks prior to the screening visit with no significant flares in  AD 
as determined by the Investigator.  
5. Validated Investigator Global Assessment -atopic dermatitis (vIGA -AD) score of Moderate 
(3) or Mild (2) at Screening. The vIGA -AD is evaluated for the entire body except scalp, 
palms, soles, and genitals.  
6. Has AD involvement (excluding scalp, palms, soles and genitals) of at least 1.0% BSA and 
no more than 14.0% BSA.  
7. Has at least two target lesions 100cm2 or greater with a difference no greater than  1 point 
in lesion TSS and at least 5 cm apart located on the trunk  (excluding genitals) or upper 
extremities (excluding palms).  
8. Male patients are eligible to participate if they agree to the following during the 
intervention period and for at least 2 days (eg, 5 terminal half -lives) after the last dose of 
study intervent ion, 
• Refrain from donating sperm  
PLUS, either:  
- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent.  
OR 
- Must agree to use contraception/barrier as detailed below:  
Agree to use a male condom and an additional highly effective contraceptive method 
as described in Appendix 2 Contraceptive and barrier guidance Section  10.2) when 
having sexual intercourse with a woman of childbearing potential (WOCBP) who is 
not currently pregnant.  
9. A female patient is eligible to participate if she is not pregnant or breastfeeding, and o ne of 
the following conditions applies:  
• Is a woman of nonchildbearing potential (WONCBP ) as defined in Appendix 2 
Contraceptive and barrier guidance ( Section  10.2). 
OR 
• Is a WOCBP and agrees to use a contraceptive method that is highly effective (with a 
failure rate of <1% per year), preferably with low user dependency, as described in 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   18 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Appendix 2 Contrac eptive and barrier guidance ( Section  10.2) during the study 
intervention period and for at least 2 days (eg, 5 termina l half -lives) after the last dose 
of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of 
reproduction during this period.  
A WOCBP must have a negative highly sensitive pregnancy test (urine and/or serum as 
required by local r egulations) within 28 days before the first administration of study 
intervention, see Section  8.2.5  Pregnancy testing.  
- If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the patient must be excluded from 
participation if the serum pregnancy result is positive.  
10. In good health as judged by the Invest igator, based on medical history, physical 
examination, serum chemistry labs, hematology values, and urinalysis.  
11. Patients are considered reliable and capable of adhering to the protocol and visit schedule, 
according to the judgment of the Investigator.  
12. Able to provide written informed consent and agreeable to the schedule of activities.  
Exclusion Criteria  
Patients are excluded from the study if any of the following criteria are met:  
1. Patients who have failed 2 or more prior systemic treatments for AD (not  including those 
who discontinued systemic treatments due to safety or tolerability issues).  
2. Patients with any serious or uncontrolled medical condition or clinically significant 
laboratory, ECG, vital signs, or physical examination abnormality that would prevent 
study participation or place the patient at significant risk, as judged by the Investigator.  
3. Patients who have received a live or attenuated vaccine in the last 12 weeks or intend to 
receive a live or attenuated vaccine during the study.  
4. Patients who cannot discontinue medications and treatments prior to the Baseline visit and 
during the study as described in the Excluded Medications and Treatments table.  
5. Has unstable AD, based on the judgement of the Investigator, or any consistent 
requirement for  high potency topical steroids to manage AD signs or symptoms.  
6. Patients who have significant active systemic or localized bacterial, viral, fungal, and 
helminth infection in the last 30 days (including known actively infected skin at or around 
a lesion of AD). Non -complicated recurrent muco -cutaneous infections such as cold sores 
are not considered exclusionary.  
7. Patients unwilling to refrain from prolonged sun exposure or use of a tanning bed or other 
artificial light emitting devices for 4 weeks prior to B aseline and during the study.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   19 of 100 
Confidential and Proprietary   01-Mar -2022  Final  8. Patients with other skin conditions that would interfere with evaluations of the effect of the 
study medication on AD, as determined by the Investigator. Patients with any condition on 
the treatment area which, in the opinion of the Investigator, could confound efficacy 
measurements.  
9. Patients with known genetic dermatological conditions that overlap with AD, such as 
Netherton syndrome.  
10. Patient has any state of immunodeficiency including but not limited to primary or 
secondary i mmunodeficiency syndromes, organ transplant (except corneal transplant), and 
previous opportunistic infections, as judged by the Investigator.  
11. Known allergies to excipients in PRN473 Gel.  
12. Previous use of a BTK inhibitor.  
13. Women who are pregnant, wishing t o become pregnant during the study, or are 
breastfeeding.  
14. Patients currently undergoing allergy (eg, food allergy testing or skin prick testing), patch 
testing, or food challenges, or plan to do so during the study.  
15. Patients who have undergone major surger y within 4 weeks prior to Day 1 or patients who 
have a major surgery planned during the study.  
16. Regular use of drugs of abuse or regular alcohol consumption within 6 months prior to the 
study defined as: an average weekly intake of >35 units for males or >3 5 units for females. 
One unit is equivalent to 8 g of alcohol: a half -pint (~240 mL) of beer, 1 glass (125 mL) of 
wine, or 1 (25 mL) measure of spirits.  
17. History of any malignancy except skin basal cell or squamous cell carcinomas in situ that 
have been rem oved and completely resolved at least 5 years ago.  
18. Any of the following laboratory abnormalities at the screening visit (identified by the 
central laboratory):  
- Absolute neutrophil count <1.5 x 109/L  
- Aspartate aminotransferase (AST) or alanine aminotransfe rase (ALT) >2 x upper limit 
of normal (ULN)  
- Total bilirubin >1.5 x ULN, (isolated bilirubin >1.5 x ULN is acceptable if total 
bilirubin is fractionated and direct bilirubin <35%)  
- Abnormal international normalized ratio (INR) test and activated partial 
thromboplastin time (aPTT) judged by the Investigator to be clinically significant  
- A platelet count <150 000/μL  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   20 of 100 
Confidential and Proprietary   01-Mar -2022  Final  19. Electrocardiogram (ECG) findings of QT corrected for heart rate (QTc) >450 msec 
(males) or >470 msec (females), poorly controlled atrial fibrillati on (ie, symptomatic 
patients or a ventricular rate above 100 beats/min on ECG), or other clinically significant 
cardiovascular abnormalities.  
20. Positive human immunodeficiency virus (HIV) antibody test.  
21. Presence of Hepatitis B surface antigen (HBsAg) and/or core antibody positive at 
screening or within 3 months prior to first dose of study intervention.  
22. Positive Hepatitis C antibody test result at screening or within 3 months prior to starting 
study inte rvention. NOTE: Patients with positive Hepatitis C antibody due to prior 
resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is 
obtained.  
23. Evidence of active or latent tuberculosis (TB) as documented by medical history an d 
examination, chest X -rays (posterior anterior and lateral), and TB testing: either a positive 
tuberculin skin test (TST; defined as a skin induration ≥5 mm at 48 to 72 hours, regardless 
of Bacillus Calmette -Guerin (BCG) or other vaccination history) or a  positive (not 
indeterminate) TB test such as QuantiFERON®-TB Gold Plus test. NOTE: The choice to 
perform a TST or a QuantiFERON -TB Gold Plus test will be made by the investigator 
according to local licensing and standard of care. The QuantiFERON -TB Gold P lus test 
can only be used in countries where it is licensed, and the use of this test is dependent on 
previous treatment(s). This test may not be suitable if previous treatment(s) produced 
significant immunosuppression.  
24. History of serious infections requir ing intravenous therapy with the potential for 
recurrence or currently active moderate to severe infection at Screening (Grade 2 or 
higher) including active coronavirus disease 2019 (COVID -19). 
25. Patients who have received the last dose of a COVID -19 vaccine  within 14 days prior to 
Day 1.  
26. Patients who are family members of the clinical study site, clinical study staff, or  Sponsor, 
or family members of enrolled patients living in the same house.  
Interim Analysis  
An interim analysis for internal decision making  may be performed. The Sponsor team that will 
analyze the data will include: a Medical Monitor, a biostatistician, a programmer, and safety 
designee. The outcome of the Interim Analysis may lead to early termination of the study in case 
of unfavorable sign als or continuation without any changes.  
See Section  9.5 for more details.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)   Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   21 of 100 
Confidential and Proprietary   01-Mar -2022  Final  1.2 SCHEMA   
 
a Two target lesions with a difference no greater than 1 point in total sign scores (TSS) will be randomly assigned in an intra -patient manner 
1:1 to PRN473 Gel, 5% or matching placebo. The two target lesions will be dosed twice daily at study site during the Blinded Period with 
the second dose application approximately 12 hours after previous dose. The investigational products could be applied by a tr ained 
medical professional a t patient’s home or an external clinic, where available, as a backup option.  
b During the Open Label Period, patients will apply PRN473 Gel, 5% BID to the all AD -affected areas, except the scalp, palms, soles, and 
genitals and should continue to treat the as signed areas throughout the Open Label Period.   
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   25 of 100 
Confidential and Proprietary   01-Mar -2022  Final  r PK samples will be collected at the following timepoints relative to the morning dose: predose and at 1, 4, and 6 hours postd ose on  Days 1 and 15; predose on Days 8 and  29; and at the Day 43 visit, approximately 
12 hours after the last dose of study intervention. The time of last application of study intervention prior to the Day 8, Da y 15, Day  29, and Day 43 visits should be recorded . The allowed time deviation window 
before a deviation is recorded for blood sample collection post dose is 15 minutes for time points up to and including 6 hour s post dose; pre -dose samples should be collected within 30 minutes prior to the next 
applicati on of study intervention.  
s Samples for blood biomarker levels should be drawn predose on Days 1, 8 and 15, and at the Day 43 visit approximately 12 hour s after the last dose of study intervention.  
t Local tolerability assessment will be performed within appro ximately 30 minutes of dosing by site staff using the symptom grading in Appendix  4 (Section  10.4.1 ) at each dosing when patients are at study site 
during dosing. During the blinded period in case the investigational products are applied at the patient’s home or external c linic, the local tolerability assessment will be performed by a trained medical professional , 
different than the pers on administering the study intervention . 
u If it becomes difficult for the patient to visit the study site, investigational products could be applied by a trained medic al professional at patient’s home or an external clinic, where available, as a backup opti on. The 
morning Visit of D1 and D8 must be conducted at the study site.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   26 of 100 
Confidential and Proprietary   01-Mar -2022  Final  2 INTRODUCTION   
2.1 STUDY RATIONALE   
Bruton’s tyrosine kinase (BTK) is an essential signaling element downstream of the B cell 
receptor (BCR), Fc -gamma receptor (Fc R), and Fc -epsilon receptor (Fc R). BTK is 
a non-receptor tyrosine kinase and is a member of the TEC tyrosine protein kinase family 
of kinases ( Mohamed  2009 ). BTK activation is critical for B cell differentiation, activation, 
and maturation. BTK also regulates the activatio n of other hematopoietic cells, such as mast cells, 
macrophages, and neutrophils primarily through Fc receptor signaling ( Rip 2018 ). Platelets 
express high levels of BTK, which is involved in collagen/glycoprotein VI (GPVI) signa ling; 
however, alternative signaling pathways exist with bypass BTK signaling to retain normal platelet 
functions and thrombus formation ( Futatani  2001 , Byrd  2013 ).  
BTK inhibition results in the down regulation of various immune cell activities including cell 
proliferation, differentiation, maturation, survival, cytokine production and the induction 
of apoptosis. Inhibition of BTK activity in B cells produces phenotypic changes consistent with 
blockade of the BCR, preventing activation, maturation, and antibody production. Inhibition 
of BTK in FcγR and FcεR expressing cells (such as macrophages or mast cells) blocks the 
inflammatory cytokine cascade driven by antibody cross -linking to the surface r eceptors 
(Chang  2011 , Xu 2012 ). Deficiency or inhibition of BTK has been shown to reduce disease 
in several immune -mediated rodent models. Pertinent to the treatment of patients with 
immune -mediated di seases, inhibitors of BTK have been shown to be anti -inflammatory in 
several rodent models of arthritis ( Chang  2011 , Di Paolo  2011 , Honigberg  2010 , Kim 2011 , 
Xu 2012 ), and lupus ( Crofford  2016 , Honigberg  2010 , Hutcheson  2012 ) with inhibition of 
proteinurea, kidney his topathology, nephritis, and cutaneous endpoints. BTK inhibitors also 
inhibit acute skin inflammation and vasculitis in antibody induced arthus reaction model 
and murine passive cutaneous anaphylaxis models ( Chang  2011 ). Several  orally administered 
BTK inhibitors, including PRN1008, SAR442168/PRN2246, evobrutinib, and fenebrutinib, 
are currently in clinical development for a range of immune -mediated diseases such as 
pemphigus, chronic spontaneous urticaria, multiple sclerosis, sy stemic lupus erythematosus, 
and rheumatoid arthritis.  
A topically applied BTK inhibitor could block the initiation and propagation of various 
immune -mediated dermatological diseases locally in the skin, with a potential clinical advantage 
of very limited systemic exposure. Such local skin mechanisms include inhibition of local 
immune cell activation, blockade of antibody -mediated Fc receptor induced inflammation, 
and recruitment and retention of neutrophils in the affected skin areas. Excessive and persist ent 
infiltration of neutrophils into tissues has a role in multiple inflammatory diseases ( Oliveira  2016 ), 
making neutrophil behavior a potential target for drug therapies, ideally to  achieve resolution of 
inflammation at a specific site without causing systemic immunosuppression.  
PRN473 is an investigational drug that is being developed as a topical agent for the treatment 
of immune -mediated dermatological diseases. PRN473 demonstrates selectivity for BTK and  a small 
number of kinases containing a homologous cysteine with durable but reversible BTK occupancy in 
biochemical assays which translates into a long duration of action in cellular systems.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   27 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Atopic Dermatitis  
Atopic dermatitis (AD) is a common, chronic, relapsing, pruritic, inflammatory skin disease. It is 
characterized by xerosis and acute (erythematous papules, vesicles, edema, exudation, crusting), 
subacute and chronic (scaly, erythematous papules and plaques, lichenification, excoriations, 
fissuring) eczematous skin lesions ( Bieber  2010 , Eichenfield  2014 , Bieber  2017 , 
Boguniewicz  2017 , Silverberg  2017 ). Typically, AD presents with an age -related morphology and 
distribution ( Eichenfield  2014 , Bieber  2017 ). 
The global prevalence of AD is estimated to be approximately 15 -30% in children 
and approximately 2-10% in adults. In  children with AD, onset occurs in 45% during the first 
6 months of life, 60% during the first year, and 90% are affected before the age of 5 ( Bieber  2010 , 
Bieber  2017, Boguniewicz  2017 , Silverberg  2017 ). Patients can experience spontaneous disease 
remission later in adolescence but up to 50% will live with AD throughout adulthood 
(Bieber  2010 , Eichenfield  2014 , Bieber  2017 , Silverberg  2017 ). 
The pathogenesis of AD is multifactorial and includes abnormalities of the skin barrier, defects in 
the innate and adaptive immune response and alterations in the resident skin microflora 
(Boguniewicz  2011 ). While there is a genetic basis for AD with loss -of-function mutations in the 
filaggrin gene ( FLG) which leads to skin barrier abnormalities, there are a  number of systemic and 
cutaneous immune abnormalities also present in AD. It is unclear if the abnormalities in skin 
barrier precedes the immune dysregulation or vice versa.  
Dysregulation of the innate immune system in AD include changes in antimicrobial peptide 
(AMP) levels, reduced toll -like receptor (TLR) function, increased mast cells in the skin, 
increased levels of serum immunoglobulin E (IgE), IgE -mediated degranulation and cytokine 
product ion, increased thymic stromal lymphopoietin (TSLP) by keratinocytes, increase in 
eosinophil infiltrates, dermal dendritic cell involvement, and  basophil recruitment and activation 
(Boguniewicz  2011 , Werfel  2016 , Weidinger  2018 ). In addition to the innate immune system, 
there are also abnormalities of the adaptive immune system in AD. Some of these abnormalities 
include an  increase in T H2 lymphocytes, increased TH2 cytokine activity A (IL -4 and IL -13) 
which initiates B -cell IgE class switching, increase in  TH1, T H17, and T H22 cells and their related 
cytokine and chemokine production ( Weidinger  2018 ). Topical treatments are the sta ndard 
therapies for patients with mild to moderate AD. Topical steroids are typically the first line 
of treatment but they are used intermittently to reduce the localized adverse effects such as skin 
atrophy, purpura, telangiectasis, and dyspigmentation ( Weidinger  2018 ). Topical calcineurin 
inhibitors (TCIs) have been used in AD as a steroid sparing treatment, however, these agents 
include a  Food and Drug Administration (FDA) black box warning of a potential increase in the 
risk of lymphoma. In addition, the use of TCIs has been limited by their inferior efficacy 
compared to the topical steroids. The  most recently FDA approved topical therapy for AD is 
crisaborole ointment, a  cAMP -specific phosphodiesterase -4 inhibitor. Crisa borole ointment has 
been shown to have a  modest improvement of disease (32%  improvement from baseline) 
compared with the vehicle alone (18 -25% improvement) ( Ahmed  2018 ). In addition, crisaborole 
has a significant localized burn ing and stinging at the site of application. Moderate efficacy 
combined with localized adverse effects has led to the reduced use of crisaborole over TCIs 
and topical steroids.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   28 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Despite progress in the treatment of mild to moderate AD, there is still a need  for a safe 
and efficacious agent that has:  
• Superior or comparable efficacy to Class 1 topical corticosteroids  
• Excellent safety and tolerability profile  
• Safe and effective as a maintenance therapy  
• No rebound effect after discontinuation  
As stated above, based on the multiple roles BTK plays in adaptive and innate immunity, a  topical 
BTK inhibitor has the potential to block the initiation and propagation of various 
immune -mediated dermatological diseases such as AD locally in the skin, with a  potential cli nical 
advantage of very limited systemic exposure.  
2.2 BACKGROUND   
2.2.1 Nonclinical studies   
PRN473 has undergone an extensive nonclinical safety evaluation. All nonclinical studies 
conducted for PRN473 are described in detail in the PRN473 Investigator’s Brochure.  
PRN473 has demonstrated slow off -rate binding kinetics to the BTK enzyme; this has 
an advantag e over fast off -rate molecules in that the longer a molecule can interact with its target, 
the longer the inhibition and resulting increase in efficacy. Slow off -rates also lead to longer 
duration of action with the potential to reduce the frequency of re -application while maximizing 
effective target inhibition at the topically applied target site. The potential clinical advantage of 
a topical PRN473 is that a longer target residence time may prolong efficacy locally with very low 
systemic exposures observe d in the plasma.  
PRN473 has been evaluated in pharmacology, PK, and toxicology studies in  mice, rats, dogs, and 
mini pigs as an oral and topical agent. Oral  PRN473 has been demonstrated to be 
pharmacologically active in mice and rats using collagen -induce d arthritis, and in dogs with 
naturally occurring spontaneous pemphigus foliaceus. This is expected since the amino acid 
sequences of mouse, rat, dog, mini pig, and  human BTK are essentially identical 
(99%  homology), with no differences across species in  the adenosine triphosphate (ATP) binding 
site where PRN473 binds. Topical PRN473 Gel has also been demonstrated to be 
pharmacologically active in mice and rats, using passive cutaneous anaphylaxis and reverse 
passive arthus as in vivo models of efficacy.  
2.2.1.1  Nonclinical pharmacology   
PRN473 is a potent, ATP -competitive, reversible  inhibitor of BTK. PRN473 demonstrates rapid 
on and slow off -rate kinetics on BTK, as well as a few closely related TEC kinase family 
members: BMX, TEC, and TXK. PRN473 does not demonstrate durable target occupancy of 
B lymphocyte kinase or interleukin ( IL)-2-inducible T -cell kinase . 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   29 of 100 
Confidential and Proprietary   01-Mar -2022  Final  PRN473 is an ATP -competitive inhibitor of BTK. Half maximal inhibitory concentration (IC 50) 
values for PRN473 were 2.1 ±0.1, 5.1  ±0.3, and 13.0 ±0.7 nM at ATP concentrations of 16, 160, 
800 µM, respectively.  
The binding characteristics of PRN473 to other kinases that had demonstrated cross -reactivity 
with PRN473 was assessed utilizing  fluorescence competition ( Kim 2011 ). These studies 
demonstrated that PRN473 exhibited durable occupancy on BMX, TEC, and TXK but not on 
BLK and ITK.  
PRN473 was screened at a concentration of 10 µM in a radioligand bindi ng assay against a  panel 
of receptors, ion channels, and transporters. In this screen, results showing an inhibition higher 
than 50% were then re -evaluated with a full IC 50 determination (A3 adenosine receptor [74.7%], 
dopamine D 2s receptor [60.4%], the ga mma -aminobutyric acid [GABA] -gated Cl- channel 
[69.3%], and dopamine transporter [94.8%]). Follow -up IC 50 assays for these receptors 
demonstrated only weak activity (IC 50 >1 μM) with no measurable IC 50 for dopamine D 2s receptor 
up to 100 μM. Activity again st all other receptors, transporters, and channels in this panel was less 
than 50%. This data reaffirms the selectivity of PRN473 for BTK and reduced potential for off 
target binding and signaling.  
The activity of PRN473 was evaluated in several cell -based  assays in which the occupancy 
of BTK and the resulting functional effects  of the compound in primary cells was assessed. 
The data from the cell -based assays support the in vitro biochemical data showing that PRN473 is 
a potent inhibitor of BTK and inhibit s the BCR mediated activation of B cells, IgE -mediated 
activation of mast cells and basophils, immunoglobulin G (IgG) -mediated activation of 
monocytes, and neutrophil migration. PRN473 demonstrated weak cytotoxicity in  cell lines not 
expressing BTK and exh ibited only weak activity on T -cell activation and  epidermal growth 
factor receptor (EGFR) activation.  
A summary of the in vitro pharmacology of PRN473 is provided Table  1. Values greater than 
5000 nM or 20  000 nM indicate no activity in the assay at the limits of the concentrations tested. 
These data are consistent with PRN473 being a potent BTK inhibitor.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   30 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Table  1 - Summary of biochemical and cellular characterization of PRN473   
Assay  Value ±SD 
BTK enzymatic IC 50  1.8 ±0.2 nM  
BTK biochemical occupancy at 24 hr  83 ±5% 
Ramos B cell occupancy IC 50  30 ±15 nM  
Occupancy of BTK in Ramos cells at 4 hr and 18 hr  91 ±3% (4 hr), 54 ±6% (18 hr)  
Occupancy of BTK in WB IC 50  364 ±112 nM  
B cell activation in HWB IC 50  274 ±95 nM  
IgG induced TNFα production in human monocytes  76 ±40 nM  
IgE induced WB human basophil CD63 activation  1130 ±510 nM  
IgE mast cell degranulation β -hexaminidase release  89 nM  
IgE mast cell degranulation histamine release  175 nM  
EGFR signaling reporter assay IC 50  >5000 nM  
Cytotoxicity in HCT -116 cells IC 50  >20 000 nM  
Abbreviations: BTK  = Bruton’s tyrosine kinase; EGFR  = epidermal growth factor receptor; IC 50 = half maximal inhibitory 
concentration; IgE  = immunoglobulin  E; IgG  = immunoglobulin  G; SD  = standard deviation; TNFα  = tumor necrosis factor 
alpha.  
In vivo phar macology studies were conducted with oral PRN473 in naturally occurring 
pemphigus foliaceus in dogs, and experimental rodent collagen -induced arthritis models.  
In all preclinical studies, PRN473 demonstrated anti -inflammatory effects with dose -dependent 
inhibition of clinical scores achieved as monotherapy. Both topical PRN473 Gel or oral PRN473 
demonstrated similar efficacy to corticosteroids (topical betamethasone dipropionate or high dose 
oral prednisolone).  
Topical PRN473 Gel inhibition of IgG antibody -mediated skin inflammation was studied in the rat 
arthus model. Topical PRN473 Gel demonstrated significant dose -dependent inhibition of passive 
arthus reaction, as measured by reduction in diameter of intra -dermal dye extravasation and OD 610nm 
from skin biopsy following IgG antibody challenge. A single administration of topical PRN473 Gel 
(over approximately 3  cm2 area) 3 hours prior to IgG antibody challenge achieved significant 
inhibition at strengths greater than 0.5% (1 mg/cm2). Similarly, multiday (3  days) application once 
daily (QD) also achieved significant inhibition at strengths greater than 0.5%. Complete responses 
equivalent to topical betamethasone dipropionate were achieved with 1% (2  mg/cm2) and 2% 
(4 mg/cm2) PRN473 Gel treatment after single  day or multiday (3 days) application. Multiday 
(3-day) treatment with QD application of PRN473 Gel revealed that the maximal efficacy equivalent 
to corticosteroids could be achieved with the lower strength of topical gel compared to single day gel 
applica tion. PRN473 Gel demonstrated prolonged inhibitory effect, maintaining significant dose -
dependent inhibition when applied 16 hours prior to challenge.  
To confirm that systemic pharmacology did not contribute to the efficacy of the topical 
PRN473  Gel, the s ystemic BTK occupancy was assessed in spleens collected terminally from the 
arthus rats on study (4 hours post challenge). Topically applied 2% (4  mg/cm2) PRN473 Gel did 
not result in measurable systemic BTK occupancy following either single dose or multid ay 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   31 of 100 
Confidential and Proprietary   01-Mar -2022  Final  (3-day) dosing, confirming that the efficacy of PRN473 Gel was driven by local skin effects 
and not by systemic pharmacology. Topical PRN473 Gel efficacy was equivalent to oral PRN473 
(10-  40mg/kg, per oral [PO], QD) and oral prednisone (10 mg/kg) treat ments in a  comparable rat 
arthus study. Taken together, these results demonstrate that topically applied PRN473 Gel can 
effectively inhibit IgG -mediated Fc γR signaling, equivalent to topical or oral corticosteroids, 
and prevent downstream IgG antibody -medi ated immune effects locally in the skin.  
There was little impact on efficacy when a single dose of 1% PRN473 Gel was administered three 
hours, one hour or 10 minutes prior to challenge for the inhibition of passive arthus reaction in 
rats. Similarly, there  was no impact on efficacy if this single dose of 1% gel was washed off prior 
to challenge, demonstrating that PRN473 Gel achieved a prolonged inhibitory effect without the 
need for continual exposure in the Rat Passive Arthus model.  
Topical PRN473 Gel dem onstrated significant dose -dependent inhibition of mouse passive 
cutaneous anaphylaxis, as measured by reduction in diameter of intra -dermal dye extravasation 
and optical density (OD 610) from skin biopsy following IgE -mediated challenge. A single 
administr ation of topical PRN473 Gel 3 hours prior to challenge achieved significant inhibition 
at strengths greater than 1% (0.6  mg/cm2). Multiday (3 days) treatment with QD application 
achieved similar levels of inhibition. Significant responses approaching topic al betamethasone 
dipropionate or antihistamine were achieved with 4% (2.4 mg/cm2) PRN473 Gel treatment. 
These  results demonstrate that topically applied PRN473 Gel (over an approximately 3 cm2 area) 
can effectively inhibit IgE -mediated FcεR signaling, equi valent to corticosteroid or antihistamine 
treatment, and prevent downstream IgE antibody -mediated immune effects locally in the skin.  
2.2.1.2  Pharmacokinetics and metabolism in animals   
Metabolism was assessed in vitro with S9 liver fractions, liver microsomes, and cryopreserved 
hepatocytes from several species. The species -specific microsomal system the highest clearance 
was observed in dog (intrinsic clearance [CL int] = 188 µL/min/mg pr otein) and the lowest 
clearance was observed in  human (CL int = 140 µL/min/mg protein).  
In the S9 fractions from mouse, rat, dog, monkey, and human, a total of 8 potential metabolites 
from PRN473 were identified. Most of the metabolites were minor (1 -10% re lative peak area 
by mass spectrometry). Two metabolites, M6 and M7, were identified as potential major 
metabolites (10% relative peak area) in a subset of species.  
In vivo metabolic profile studies of oral PRN473 in mice, rat, dog, monkey, and mini pig 
identified three major metabolites: the reduced metabolite (PRN684), the hydrolyzed metabolites 
(PRN834, PRN835), and the oxidation metabolite (PRN664). Overall, the metabolites observed in 
all animal species were similar. No unique human metabolites have be en detected from studies 
conducted to date.  
Plasma protein binding was >99% in all species and the blood to plasma ratio for distribution in 
evaluated species was ranged from 0.43 (in dog) to 0.66 (in monkey).  
CYP450 inhibition and induction studies have also been completed. The results of the in vitro 
inhibition studies with 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 showed that PRN473 does not 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   32 of 100 
Confidential and Proprietary   01-Mar -2022  Final  significantly inhibit CYP450 enzymes (IC 50 >6 μM across isoforms). In a CYP induction study no 
induction was seen with PR N473 at 10 μM for the tested isoforms of CYP 1A2, 2B6, and  3A4.  
The in vivo PK of PRN473 was assessed in rats, dogs, and mini pigs via intravenous (IV) and PO 
administration. All species demonstrated good bioavailability following oral administration. 
Oral bioavailability was lowest in dog (7%) and comparable in mini pig (approximately 17%) and 
rat (21%). Following topical administration of a single dose in dogs and mini pigs, the systemic 
exposure was limited (<10  ng/mL for most of the samples) and lower t han the exposure observed 
following oral administration in  both rat and mini pig species, suggesting that the topical 
administration likely demonstrate limited systemic absorption and lower concentration levels 
compare to oral administration in  human. Nonc linical PK studies following IV and PO 
administration of PRN473 are described in detail in the PRN473 Investigator’s Brochure.  
2.2.1.3  Nonclinical toxicology   
Dermal administration of PRN473 Gel to mini pigs at 0.5% (0.05 mg/cm2), 2% (0.2 mg/cm2), 
and 10% (1 mg/cm2), strengths for at least 28 days was well tolerated. There were no 
PRN473 -related changes. The maximum tolerated dose was not reached even at the highest 
dose of 10% when adm inistered QD over a 10 % body surface area (approximately 400 cm2 
at a gel application rate of 10 mg/cm2/day) of mini pig. At the low dose (0.5% gel) due to the low 
exposure levels, the kinetic properties of PRN473 were not able to be determined, except on e 
animal on Day 28. The maximum concentrations observed on Day 7 and Day 28, following 
10% gel application were 2.32 ng/mL and 3.17ng/mL, respectively. The corresponding area under 
the concentration -time curve (AUC) values were 11.3 ng ×hr/mL and 25.1 ng ×hr/mL, respectively. 
Additionally, the 10% PRN473 Gel did not cause ocular irritation and the PRN473  Gel may have 
the potential to be a contact sensitizer as discussed in the Investigators Brochure.  
In a 28 -Day oral rat study, all treated animals had measura ble systemic exposure following 
both single and repeated QD oral PRN473 administration at doses of 150 and 500 ng/mL. 
PRN473 mean maximum plasma concentration (C max) values increased less than proportionally 
and area under the plasma concentration -time cur ve from time zero to the last measurable 
concentration (AUC 0-last exposures increased proportionally with increases in dose. No  significant 
accumulation was observed (as assessed by mean C max and AUC 0-last on Day  28 vs Day 1). 
A higher exposure was observe d in females then males as assessed by mean C max and AUC 0-last. 
Treatment with PRN473 was well tolerated. Liver weight changes with associated hepatocellular 
hypertrophy were observed following oral treatment with 500 mg/kg. Based on these findings, the 
no-observed -adverse -effect level (NOAEL) in rats is considered 150  mg/kg (C max: female 
713 ng/mL, male 308 ng/mL; AUC: female 6600 ng ×hr/mL, male 3170  ng×hr/mL).  
In a 28 -day oral dog study, all treated animals had measurable systemic exposure. PRN473 
plasma exposure (as assessed by average C max and AUC 0-last) increased in a greater than dose 
proportional manner over the full dose range on both collection days, with the exception of 
Day 28 male C max values. PRN -473 plasma exposure (as assessed by mean C max and AUC 0-last) 
increased comparing Day 28 values to Day1 values. Sex differences were noted when comparing 
PRN473 plasma exposure on Day 1 and Day 28 values. Treatment with PRN473 was well 
tolerated. Based on these findings, the NOAEL is at least 400  mg/kg (C max: female 2220 ng/mL, 
male 3390 ng/mL; AUC: female 10  600 ng ×hr/mL, male  23 900 ng ×hr/mL).  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   33 of 100 
Confidential and Proprietary   01-Mar -2022  Final  In a 13 -week oral rat study, treatment with PRN473 was well tolerated at the dosages tested. 
Administration of 60 or 150 mg/kg PRN473 was associated with dose -depe ndent increases 
in liver weights for males and females with no histomorphologic correlates. Based on these 
findings, the NOAEL in rats following was considered to be above 150 mg/kg (C max: female 
726 ng/mL, male 339ng/mL; AUC: female 4590 ng ×hr/mL, male 2940 ng ×hr/mL).  
In a 13 -week oral dog study, treatment of PRN473 at the dosages tested was well tolerated. 
Administration of any dosage of PRN473 tested was associated with decreased activity 
and reduced body weight in females. Administration of 400 mg/kg  in females was associated with 
decreased food consumption. Based on these findings, the NOAEL in dogs following oral dosing 
is considered to be 400 mg/kg (C max 2220 ng/mL and AUC 8860ng ×hr/mL) in males and 
120 mg/kg (C max 918 ng/mL and AUC 3110 ng ×hr/mL) in females.  
2.2.2 Clinical studies   
First-in-human administration of PRN473 in 38 healthy volunteers occurred in completed Phase  1 
Study PRN473 -001 using the PRN473 liquid and tablet fo rmulations. The results following oral 
dose administration up to a single dose of 600 mg (the maximum dose) demonstrated very limited 
systemic exposure (<10 ng/mL) of PRN473.  
Due to the very low systemic exposure, PRN473 was reformulated into a topical ge l and then 
tested in two Phase 1 studies. PRN473 topical has been administered to 42 healthy volunteers in 
Study PRN473 -0002 and 21 patients with IgE -mediated allergies in Study PRN473 -0003. Plasma 
concentrations of PRN473 were measured in PRN473 -0002 but not in PRN473 -0003. The results 
from PRN473 -0002 showed that the majority of PK samples were not measurable (ie,  below the 
quantitation limit). The samples that were measurable were too low to support computation of PK 
parameters following topical applicat ion in healthy participants.  
The individual studies are summarized Table  2 in below.  
Table  2 - Summary of PRN473 clinical studies   
Study Number/  
Formulation  Population  
(sample size)  Study Purpose  Dose Levels  Status  
Phase 1  
PRN473 -0001/ 
liquid and tablet  Healthy 
volunteer  
Part A  
(N = 38 active)  
Part B (N = 0) Single and Repeat 
dose to assess safety, 
tolerability, and PK  
(First -in-Human 
Study)  50, 100, 200, 600 mg  
(6, 8, or 10 active; 2  PBO 
per group in Part A)  Completed  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   34 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Study Number/  
Formulation  Population  
(sample size)  Study Purpose  Dose Levels  Status  
PRN473 -0002/ 
topical gel  Healthy 
volunteer  
(N = 60)  Single and Repeat 
dose to assess safety, 
tolerability, and PK  0.5, 2.0, 5.0%  
(8 active; 2  PBO in each 
of 5 single -dose cohorts)  
5.0%  
(8 active; 2 PBO in 
a repeat -dose cohort)  Completed  
PRN473 -0003/  
topical gel  Patients with 
IgE-mediated 
allergies  
(N = 21)  Single doses to assess  
pharmacologic 
activity, safety, 
and tolerability  0.5, 2, 5%; or PBO  Completed  
Abbreviations: MD  = multiple -dose; PBO  = placebo; PK  = pharmacokinetic.  
Available data from the Phase 1 studies are summarized in the PRN473 Investigator’s Brochure.  
2.3 BENEFIT/RISK ASSESSM ENT   
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of PRN473 may be found in the Investigator’s Brochur e. 
2.3.1 Risk assessment   
No risks other than those previously mentioned in the Investigator’s Brochure are known at this 
time.  
2.3.2 Benefit assessment   
Patients may benefit from having regular clinical and laboratory evaluations throughout the study. 
There may be no direct health benefit for patients from receipt of study inter vention.  
2.3.3 Overall benefit/Risk assessment   
PRN473 is being developed for topical skin application for the treatment of immune -mediated 
dermatological diseases.  
The toxicity potential of PRN473 is well characterized in in vitro assays, safety pharmacology 
studies, and repeat dose oral and topical toxicity studies in multiple animal species. PRN473 has 
also been well tolerated when orally administered in single asc ending doses to healthy volunteers. 
The overall preclinical and clinical profile of PRN473 to date continues to  favor continued 
investigation of PRN473.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   35 of 100 
Confidential and Proprietary   01-Mar -2022  Final  3 OBJECTIVES AND ENDPO INTS   
Table  3 - Objectives and endpoints   
Objectives  Endpoints  
Primary   
Safety:  
To assess the safety and tolerability of PRN473 Gel, 5% 
versus placebo administered BID up to 6  weeks in 
patients with mild to moderate AD  Safety:  
• Incidence and severity of AEs  
• Changes in vital signs, ECGs, and laboratory tests  
• Assessment of local cutaneous tolerability: 
incidence and severity of  application -site events 
such as burning/stinging, itching, and erythema   
Secondary   
PK: To evaluate the plasma PK of PRN473 following 
administration of multiple topical doses of PRN473 
Gel, 5% for 42  days in patients with mild to moderate 
AD • PK: Plasma PRN473 concentrations at specified 
timepoints  
Exploratory  
• Biomarker: To evaluate blood and skin changes in 
protein and RNA expression, lymphocyte 
infiltration, and epidermal thickness following 
treatment with PRN473 Gel, 5% at Days  8 and 15  • Biomarker: Change from Baseline in biomarkers 
using blood samples, skin tape stripping, and  skin 
biopsy  
• Efficacy: To evaluate the preliminary efficacy 
following double -blind treatment with PRN473 
Gel, 5% compared to placebo at Days 8 and 15  Efficacy During Blinded Period:  
• Change from Baseline in lesion TSS at Days 8 and 
15 
• Change from Baseline in daily lesional PP -NRS 
score up to Day 15  
• Change from Baseline in lesional validated IGA 
score at Days  8 and 15  
• Lesional validated IGA response (proportion of 
patients with a  valida ted IGA score of 0 or 1 and 
≥2-grade improvement from Baseline) at Days 8 
and 15  
• Efficacy: To evaluate the preliminary efficacy 
following open -label treatment with PRN473 Gel, 
5% at Days  29 and 43  Efficacy During Open -Label Period  
• Change from Baseline in TSS for the 2 target 
lesions at Days 29 and 43.  
• Change from Baseline in EASI at Days 29 and 43  
• Change from Day 15 in EASI to Days 29 and  43 
• Proportion of patients with EASI 50, EASI 75, 
and EASI  90 from Day 15 to Days 29 and 43  
• Change in PP -NRS from Day 15  to Days 29 and 43  
• Proportion of patients achieving at least 3 -point 
reduction from Day 15 in PP -NRS at Days 29 
and 43 
• Proportion of patients achieving at least a 4 -point 
reduction from Day 15 in PP -NRS at Days  29 
and 43 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   36 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Objectives  Endpoints  
 • Change from Day 15 in weekly mean  of PP -NRS at 
Days 29 and  43 
• Proportion of patients achieving at least 2 grade 
reduction in vIGA -AD to clear (vIGA -AD 0) or 
almost clear (vIGA -AD 1) from Day 15 to Days 29 
and 43  
• Change from Day 15 in SCORAD at Days 29 and 
43 
• Change from Day 15 in percenta ge of treatable 
BSA at Days 29 and 43  
• Change from Baseline in POEM at Days 15, 29, 
and 43  
• Change from Baseline in DLQI at Days 15, 29, and 
43 
 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   37 of 100 
Confidential and Proprietary   01-Mar -2022  Final  4 STUDY DESIGN   
4.1 OVERALL DESIGN   
This is a Ph2a study that consists of a double -blind, intra -patient placebo -controlled treatment 
period and an open -label uncontrolled treatment period with objective to evaluat e the safety, 
tolerability, PK and preliminary efficacy of PRN473 in up to 40 patients with mild to moderate 
AD. All  patients are required to apply an emollient (except urea -containing or medicated 
emollients that are regulated as medical device) daily fro m Day -7 to Day 1 (see Section  6.2). 
On Day 1 (Baseline) of the Blinded Period, 2 target lesions with a difference no greater than 
1 point in TSS will  be randomly assigned to treatment in an intra -patient 1:1 manner, one lesion  to 
PRN473 Gel, 5%, and the other to matching placebo. PRN473 Gel, 5% and matching placebo are 
weighed and  applied BID (morning and evening) at a  quantity of approximately 2.5  mg/cm2 to 
a 100 cm2 area of each target lesion on Days  1- 14 (Blinded Period).  The investigational products 
will be applied at the study site, at the patient’s home , or at an external clinic, where available.  
During the Blinded Period, if the target lesion is less than 100 cm2, the application area should 
include surrounding nonlesio nal skin (note: two target lesion skin biopsy specimens on Days 1 
and 15 are only on lesional skin); if the target lesion is larger than 100 cm2, only 100 cm2 of the 
lesion should be marked and treated. On  Days 15 -42 (Open -Label Period), patients are instr ucted 
to apply PRN473 Gel, 5% BID to all AD -affected areas in a thin layer (excluding the scalp, 
palms,  soles and genitals) and should continue to treat the assigned areas throughout the Open 
Label Period.  
Safety assessments include application site tolera bility assessments (Appendix  4, Section  10.4.1 ), 
vital signs, ECGs, physical examination, safety labs, and AEs.  
To evaluate the PK (plasma concentrations) and biomarker of PRN473, blood samples will be 
collected at study visits accordingly to the SoA ( Section  1.3). 
Efficacy assessments of:  
• The lesional PP -NRS will be administered daily predose during the Blinded Period 
(Days  1-14) and at predose Day 15.  
• The lesional validated IGA will be performed predose at Baseline (Day 1), and Day s 8 and 
15.  
• The lesion TSS (Appendix 4,  Section  10.4.3 ) will be performed predose at Baseline 
(Day  1), Days 8, 15, and 29, and  at End of Study/Early Termination visit (Day  43). 
• The EASI, the POEM, and  the DLQI will be performed predose at Baseline  (Day 1), 
Days  15 and 29, and  at End of Study/Early Termination visit (Day  43). 
• The vIGA -AD (Appendix 4, Section  10.4.2 ) will be performed, predose at Days 15 and 
29, and  at End of Study/Early Termination visit (Day  43). 
• The SCORAD will be performed predose at Days 15 and 29, and  at End of Study/Early 
Termination visit (Day  43). 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   38 of 100 
Confidential and Proprietary   01-Mar -2022  Final  • The PP -NRS will be administered daily predo se before patient morning application  during 
the Open -Label Period (Days 15 -42) and at  End of Study/Early Termination visit 
(Day  43).  
• The percentage of treatable BSA will be calculated at Screening, Days 15 and  29, and 
at End of Study/Early Termination vi sit (Day  43). 
To be included in the population analyzed for efficacy, the patient must have received at least 
80% of prescribed study intervention in the Blinded Period and/or at least 80% of prescribed 
study intervention in the Open -Label Period.  
Skin tape stripping (STS) will be performed predose on Days 1, 8 (optional), 15, 29, and at 
Day 43 for the two  target lesions and on Day 1 for the normal skin. For a minimum of 20 patients 
(may be reduced to 15  patients if there is an impact on enrollment from COVID -19, a  4 or 5 mm 
punch skin biopsy will be collected from each target lesion on Days  1, 15, and  29 (optional) and 
from normal skin on Day 1 . The lesional biopsy specimens at Days 15 and 29 will be collected in 
the vicinity of the Day 1 (Baseline lesional sample) biopsy but must be at least 1 cm away from 
the prior biopsy site. If the target  lesion cleared after Day 1 and before Day 15, the biopsy 
specimen will be taken from the lesional skin location of the target area identified at Baseline.  
Additional information regarding study assessments and their timing is located in the Schedule of 
Activities ( Section  1.3). 
Inclusive of an up to 5 -week screening period, a 6 -week treatment period, end of study 
assessm ents 1 day after last dose, and a safety follow -up phone call 2 weeks after last dose, the 
participation will take approximately 13 weeks.  
Due to the COVID -19 pandemic, safety measures may be implemented to ensure continued 
supply of study medication and s afety monitoring for patients. When the COVID -19 pandemic 
resolves, the measures will be repealed back to the previous state as government rules 
and benefit/risk assessment allow.  
As required, these approaches (in accordance with local regulations) will be  documented in site 
guidance materials.  
Additionally, during the COVID -19 pandemic, drug supply may be sent to patients when the 
patient is not able to travel to the site or the site cannot host a patient visit. At -site study visits as 
outlined in the Sche dule of Activities may be changed to a remote visit (eg, phone call, video call, 
or visiting nurse) as needed to address the COVID -19 restrictions.  
If the change to remote visits is implemented due to COVID -19 to protect the safety 
and well-being of patien ts, the inability to perform/obtain protocol -specified assessments at 
a required study visit will be documented.  
4.2 SCIENTIFIC RATIONALE  FOR STUDY DESIGN   
See Section  2.1. 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   39 of 100 
Confidential and Proprietary   01-Mar -2022  Final  4.3 JUSTIFICATION FOR DO SE  
The do se of PRN473 selected for topical administration during the Blinded Period on Days 1 -14 
in PRN473 -0005 (ACT17131) is PRN473 Gel, 5% or matching placebo at approximately 
2.5 mg/cm2 over a 100 cm2 area encompassing each target lesion BID (approximately 12 hours 
apart). During the Open -Label Period on Days 15 -42, PRN473 Gel, 5% at 2.5  mg/cm2 will be 
applied BID to all AD -affected areas excluding the scalp, palms, soles, and genitals over a body 
surface area of up to 14%. This dose is in the range of those as sociated with biological activity 
based on preclinical disease models and is therefore considered appropriate to evaluate in this 
initial assessment of PRN473 Gel efficacy in patients with AD.  
The proposed dosing regimens are supported by clinical safety data from the PRN473 -0002 study. 
The total daily dose during the Blinded Period of the study (25 mg PRN473 active pharmaceutical 
ingredient [API] per day) is approximately 7 -fold lower than the daily dose applied in the multiple 
dose arm of PRN473 -0002 (17 5 mg PRN473 API per day). This dose was safe and well -tolerated 
and there were no serious adverse events (SAEs) or AEs that led to discontinuation.  
In the Open -Label Period, the dosing regimen of PRN473 5% (w/w) gel at 2.5 mg/cm2 gel over 
14% BSA BID will provide a daily PRN473 (API) dose of 665 mg to a patient with a total body 
surface area of 1.9  m2. This is less than the dose of 700 mg PRN473 (API), which was the highest 
dose administered in the PRN473 -0002 single ascending dose/multiple dose study in he althy 
participants. This dose was safe and well -tolerated and there were no SAEs or AEs that led to 
discontinuation.  
Patients will measure the dose by the fingertip unit method and the expected dose variability when 
the compound is topically self -applied by this method may be up to two -fold excess of compound 
which is reasonably below the safety margin.  
In both the Blinded  and Open -Label  Periods,  the locally  applied  dose of 0.125  mg API/cm2 is the 
same  as that evaluated  in the multiple  dose arm of the PRN4 73-0002  study  and is 4-fold lower  
than the highest  dose that was evaluated  in the single  ascending  dose part of PRN473 -0002.  
In addition,  this dose is approximately  8-fold lower  than the maximum dose (1 mg API/cm2) used 
in the 28 -day mini pig dermal repeat ed dose study (DVR489), in which there were no PRN473 -
related changes, providing further support for the safety of the locally applied PRN473 dose of 
0.125 mg API/cm2. 
Systemic PRN473 exposures following administration of PRN473 Gel at all dose levels in s tudy 
PRN473 -0002 were negligible to nonexistent, with insufficient data to estimate PK parameters 
as plasma PRN473 concentrations were only sporadically detectable in a few participants. 
However, the safety of systemic PRN473 has been characterized in dog and rat toxicity studies in 
which the NOAEL doses in both species were  substantially  higher  than the exposures  following  
oral administration  to humans.  On Day 28, the male  and female  rat (most  sensitive  species)  mean  
PRN473  Cmax values  were  308 ng/mL  and 713 ng/mL,  respectively.  At Week  13, the male  
and female  rat mean  PRN473  Cmax values  were  339 ng/mL  and 726 ng/mL,  respectively.  These  
systemic  exposures  represent  a very large  safety  margin  compared  to measured  exposures  of 
PRN473  following  topical  adminis tration  of a 10% gel to the mini pig and following  oral 
administration  of PRN473  in healthy  volunteers  (Study  PRN473 -001).  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   40 of 100 
Confidential and Proprietary   01-Mar -2022  Final  In summary,  the totality  of the clinical  and preclinical  data supports  the evaluation  of the dosing  
regimen  of 5% (w/w)  PRN473  Gel at 2.5 mg gel/cm2 over up to 14% BSA  in patients  with AD. 
4.4 END OF STUDY DEFINIT ION   
The end of the study is defined as the date of the last visit of the last patient in the study.  
A patient is considered to have completed the study if he/she has completed all phases of the 
study including the Day 43 and Day 56 safety follow up phone call.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   41 of 100 
Confidential and Proprietary   01-Mar -2022  Final  5 STUDY POPULATION   
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known 
as protocol waivers or exemptions, is not permitted.  
5.1 INCLUSION CRITERIA   
Patients are eligible to be included in the study only if all the following criteria are met:  
1. Male and female adults 18 to 70 years of age (inclusive) at the time of  informed consent.  
2. Diagnosed with mild to moderate AD, meeting at least 3 major and  3 minor criteria  
according to Hanifin and Rajka ( Hanifin  1980 ; Appendix  4, Section  10.4.4 ) prior to or at 
the Screening visit.  
3. History of AD for at least 6 months as determined by the Investigator through patient 
interview.  
4. Stable disease for the 4 weeks prior to the screening vis it with no significant flares in AD 
as determined by the Investigator.  
5. Validated Investigator Global Assessment -atopic dermatitis (vIGA -AD) score of Moderate 
(3) or Mild (2) at Screening. The vIGA -AD is evaluated for the entire body except scalp, 
palms, so les and genitals.  
6. Has AD involvement (excluding scalp, palms, soles and genitals) of at least 1.0% BSA and 
no more than 14.0% BSA.  
7. Has at least two target lesions 100 cm2 or greater with a difference no greater than  1 point 
in lesion TSS and at least 5 cm apart located on the trunk (excluding genitals) or upper 
extremities (excluding palms)  
8. Male patients are eligible to participate if they agree to the following during the 
intervention period and for at least 2 days (eg, 5 terminal half -lives) after the las t dose of 
study intervention,  
• Refrain from donating sperm  
PLUS, either:  
- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent.  
OR 
- Must agree to use contraception/barrier as detailed below:  
Agree to use a male condom and an additional highly effective contraceptive method 
as described in Appendix 2 Contraceptive and barrier guidance ( Section  10.2) when 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   42 of 100 
Confidential and Proprietary   01-Mar -2022  Final  having sexual intercourse with a woman of childbearing potential (WOCBP) who is 
not currently pregnant.  
9. A female patient is eligible to participate if she is not pregna nt or breastfeeding, and one of 
the following conditions applies:  
• Is a WONCBP as defined in Appendix 2 Contraceptive and barrier guidance 
(Section  10.2). 
OR 
• Is a WOCBP and agrees to use a contraceptive method that is highly effective (with a 
failure rate of <1% per year), preferably with low user dependency, as described in 
Appendix 2 Contraceptive and barrier guidance ( Section  10.2) during the study 
intervention period and for at least 2 days (eg, 5 terminal half -lives) after the last dose of 
study intervention and agrees not to donate eggs (ova, oocytes) for the purpose  of 
reproduction during this period.  
A WOCBP must have a negative highly sensitive pregnancy test (urine and/or serum as 
required by local regulations) within 28 days before the first administration of study 
intervention, see Section  8.2.5  Pregnancy testing.  
- If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In s uch cases, the patient must be excluded from 
participation if the serum pregnancy result is positive.  
10. In good health as judged by the Investigator, based on medical history, physical 
examination, serum chemistry labs, hematology values, and urinalysis.  
11. Patients are considered reliable and capable of adhering to the protocol and visit schedule, 
according to the judgment of the Investigator.  
12. Able to provide written informed consent and agreeable to the schedule of activities.  
5.2 EXCLUSION CRITERIA   
Patients are excluded from the study if any of the following criteria are met:  
1. Patients who have failed 2 or more prior systemic treatments for AD (not including those 
who discontinued systemic treatments due to safety or tolerability issues).  
2. Patients with any serious or uncontrolled medical condition or clinically significant 
laboratory, ECG, vital signs, or physical examination abnormality that would prevent 
study participation or pla ce the patient at significant risk, as judged by the Investigator.  
3. Patients who have received a live or attenuated vaccine in the last 12 weeks or intend to 
receive a live or attenuated vaccine during the study.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   43 of 100 
Confidential and Proprietary   01-Mar -2022  Final  4. Patients who cannot discontinue medications and treatments prior to the Baseline visit and 
during the study listed in the Excluded Medications and Treatments table.  
5. Has unstable AD, based on the judgement of the Investigator, or any consistent 
requirement for high potency topical steroids to manage AD signs or symptoms.  
6. Patients who have significant active systemic or localized bacterial, viral, fungal, and 
helminth infection in the last 30 days (including known actively infected skin at or around 
a lesion of AD) . Non-complicated recurrent muco -cutan eous infections such as cold sores 
are not considered exclusionary.  
7. Patients unwilling to refrain from prolonged sun exposure or use of a tanning bed or other 
artificial light emitting devices for 4 weeks prior to Baseline and during the study.  
8. Patients wi th other skin conditions that would interfere with evaluations of the effect of the 
study medication on AD, as determined by the Investigator. Patients with any condition on 
the treatment area which, in the opinion of the Investigator, could confound effic acy 
measurements.  
9. Patients with known genetic dermatological conditions that overlap with AD, such as 
Netherton syndrome.  
10. Patient has any state of immunodeficiency including but not limited to primary or 
secondary immunodeficiency syndromes, organ transpla nt (except corneal transplant), and 
previous opportunistic infections, as judged by the Investigator.  
11. Known allergies to excipients in PRN473 Gel.  
12. Previous use of a BTK inhibitor.  
13. Women who are pregnant, wishing to become pregnant during the study, or ar e 
breastfeeding.  
14. Patients currently undergoing allergy (eg, food allergy testing or skin prick testing), patch 
testing, or food challenges, or plan to do so during the study.  
15. Patients who have undergone major surgery within 4 weeks prior to Day 1 or patients who 
have a major surgery planned during the study.  
16. Regular use of drugs of abuse or regular alcohol consumption within 6 months prior to the 
study defined as: an average weekly intake of >35 units for males or >35 units for females. 
One unit is eq uivalent to 8 g of alcohol: a half -pint (~240 mL) of beer, 1 glass (125 mL) of 
wine, or 1 (25 mL) measure of spirits.  
17. History of any malignancy except skin basal cell or squamous cell carcinomas in situ that 
have been removed and completely resolved at lea st 5 years ago.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   44 of 100 
Confidential and Proprietary   01-Mar -2022  Final  18. Any of the following laboratory abnormalities at the screening visit (identified by the 
central laboratory):  
- Absolute neutrophil count <1.5 x 109/L  
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x upper limit 
of norm al (ULN)  
- Total bilirubin >1.5 x ULN, (isolated bilirubin >1.5 x ULN is acceptable if total 
bilirubin is fractionated and direct bilirubin <35%)  
- Abnormal international normalized ratio (INR) test and activated partial 
thromboplastin time (aPTT) judged by t he Investigator to be clinically significant  
- A platelet count <150 000/μL  
19. Electrocardiogram (ECG) findings of QT corrected for heart rate (QTc) >450 msec 
(males) or >470 msec (females), poorly controlled atrial fibrillation (ie, symptomatic 
patients or a v entricular rate above 100 beats/min on ECG), or other clinically significant 
cardiovascular abnormalities.  
20. Positive human immunodeficiency virus (HIV) antibody test.  
21. Presence of Hepatitis B surface antigen (HBsAg) and/or core antibody positive at 
screening or within 3 months prior to first dose of study intervention.  
22. Positive Hepatitis C antibody test result at screening or within 3 months prior to starting 
study inte rvention. NOTE: Patients with positive Hepatitis C antibody due to prior 
resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is 
obtained.  
23. Evidence of active or latent tuberculosis (TB) as documented by medical history an d 
examination, chest X -rays (posterior anterior and lateral), and TB testing: either a positive 
tuberculin skin test (TST; defined as a skin induration ≥5 mm at 48 to 72 hours, regardless 
of Bacillus Calmette -Guerin (BCG) or other vaccination history) or a  positive (not 
indeterminate) TB test such as QuantiFERON® -TB Gold Plus test. NOTE: The choice to 
perform a TST or a QuantiFERON -TB Gold Plus test will be made by the investigator 
according to local licensing and standard of care. The QuantiFERON -TB Gold P lus test 
can only be used in countries where it is licensed, and the use of this test is dependent on 
previous treatment(s). This test may not be suitable if previous treatment(s) produced 
significant immunosuppression.  
24. History of serious infections requir ing intravenous therapy with the potential for 
recurrence or currently active moderate to severe infection at Screening (Grade 2 or 
higher) including active coronavirus disease 2019 (COVID -19). 
25. Patients who have received the last dose of a COVID -19 vaccine  within 14 days prior to 
Day 1.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   45 of 100 
Confidential and Proprietary   01-Mar -2022  Final  26. Patients who are family members of the clinical study site, clinical study staff, or  Sponsor, 
or family members of enrolled patients living in the same house.  
5.3 LIFESTYLE CONSIDERAT IONS   
5.3.1 Meals and dietary restrictions   
There are no dietary restrictions in this study.  
5.3.2 Caffeine, alcohol, and tobacco   
Patients will be excluded from the study if there is a history of chronic alcohol abuse within 
6 months prior to the first study intervention administration.  
5.3.3 Activity   
Given that natural outdoor ultraviolet (UV) exposure can help treat AD lesions, patients must 
limit excessive UV exposure when possible (including refraining from suntanning) and should use 
sunblock SPF 30 or above when outdoor activities are planned.  
Patients must keep the topical gel on the skin for at least 4 hours after application of study 
intervention by refraining from swimming, bathing, using a sauna, or washing the tre ated areas.  
After applying the topical gel, patients should avoid wiping the study intervention off the area 
or covering the treated areas with wraps or bandages. To avoid ingestion of study intervention, 
wash hands immediately after application of topical  gel, and avoid putting hands in mouth.  
5.4 SCREEN FAILURES   
Screen failures are defined as patients who consent to participate in the study but are subsequently 
not enrolled. A minim al set of screen failure information is required to ensure transparent 
reporting of screen failure patients. Minimal information includes informed consent, demography, 
eligibility criteria, and any concomitant medications and AEs.  
5.5 CRITERIA FOR TEMPORA RILY DELAYING ADMINISTRAT ION OF STUDY 
INTERVENTION    
Not applicable.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   46 of 100 
Confidential and Proprietary   01-Mar -2022  Final  6 STUDY INTERVENTION A ND CONCOMITANT THERAPY   
Study intervention is defined as any investigational intervention(s), marketed product(s), or 
placebo intended to be administered to a study patient according to the stud y protocol.  
6.1 STUDY INTERVENTION ( S) ADMINISTERED   
Table  4 - Study intervention   
 PRN473  Placebo  
Drug Name  PRN473 Gel, 5%  PRN473 Gel, Placebo  
Type  Drug  Placebo  
Dose Formulation  White to off -white gel suspension 
containing PRN473, inactive 
ingredients (propylene glycol, 
glycerin, polysorbate 80, medium 
chain triglycerides, Carbopol  980, 
preservatives [methylparaben 
and propylparaben], and water). The 
gel suspension is adjusted to pH 5.  White to off -white gel suspension 
containing the same inactive 
ingredients, except that titanium 
dioxide used to match the color of 
PRN473 active ing redient.  
Unit Dose Strength(s)  5% (w/w)  0% 
Dosage Level(s)  5% (w/w) gel at 2.5 mg gel/cm2 over 
100 cm2 BID (Blinded Period) or up to 
14% BSA BID (Open -Label Period)  Matching placebo at 2.5 mg gel/ cm2 
over 100 cm2 BID (Blinded Period)  
Route of Administration  Topical  Topical  
Use Experimental  Experimental  
IMP or NIMP  IMP IMP 
Sourcing  Provided centrally by the Sponsor  Provided centrally by the Sponsor  
Packaging and Labeling  PRN473 Gel products are filled into 
aluminum tubes (approximately 30  g 
in each aluminum tube).  Placebo Gel products are filled into 
aluminum tubes (approximately 30  g 
in each aluminum tube).  
Former Name(s) or Alias(es)  SAR444727  not applicable  
Abbreviations: API  = active pharmaceutical ingredient; IMP  = investigational medicinal product; NIMP  = non-investigational 
medicinal product.  
6.2 PREPARATION/HANDLING /STORAGE/ACCOUNTABIL ITY  
The Sponsor will supply the study intervention to the study site. The study intervention provided 
for this study was manufactured under Current Good Manufacturing Practices (CGMP) 
and will be suitable for human use. The Sponsor is responsible for the prepa ration and labelling 
and providing details of batch numbers, safety, and stability data. The study intervention will be 
labelled in  accordance with local regulatory requirements and will be shipped at a temperature of 
2-8oC. 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   47 of 100 
Confidential and Proprietary   01-Mar -2022  Final  The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are reported 
and resolved before use of the study intervention. The recommended storage condition is 2 -8°C 
(Invest igator’s Brochure).  
Only patients enrolled in the study may receive study intervention, and only authorized study staff 
(eg, site staff, trained medical professional, home health vendor, external clinic staff, etc) may 
supply or administer study interventi on during the Blinded Period . At the study site, all study 
intervention must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access limited to the 
Investigat or and authorized site staff.  
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disp osition records). When  the study is completed, the 
Investigator will return or destroy any used and unused trial medication (eg, empty, partially used, 
and unused containers) to the Sponsor as requested.  
The Investigator or designee is responsible for the education of site staff as to the correct 
administration of the study intervention.  
When operationally feasible and if treating physician determines that it is appropriate and safe,  
administration of IMP may occur at study patient’s home or at an extern al clinic by a trained 
medical professional. These approaches will only be implemented if allowed by local regulations, 
and agreed by the treating physician, while ensuring blinding measures are maintained.   
Patients are required to apply an emollient (exc ept urea -containing or medicated emollients that 
are regulated as medical device) daily from Day -7 to Day 1. Beginning on Day 1, emollient is to 
be applied only on untreated areas (eg, may not be used on the 2 target lesions during Days 1 -14, 
and may not be used on any parts of the body being treated with PRN473 Gel, 5% during 
Days  15-42). 
PRN473 Gel, 5% or matching placebo will be removed from storage at 2 -8°C and  held at room 
temperature for at least 30 minutes prior to administration. Site staff or trai ned medical 
professional will apply PRN473 Gel, 5% or matching placebo with nitrile gloves to the 2 target 
lesions per the randomization assignment, as follows:  
• Approximately 2.5 mg gel/cm2 to each 100 cm2 target lesion on Days 1 -14. If  the target 
lesion i s less than 100 cm2, the application area should include surrounding nonlesional 
skin; if the target lesion is larger than 100 cm2, only 100 cm2 of the lesion should be 
marked and treated.  
• On Days 15 -42 (open -label period), patients are instructed to appl y PRN473 Gel, 5%  BID 
to all AD -affected areas in a thin layer, excluding the scalp, palms, soles, and genitals.  
Under no circumstances will the Investigator supply study intervention to a third party (except for 
direct to patient [DTP] shipment  or direct t o designated clinic for home health care option if 
patient is not able to be dosed at home , for which a courier company has been approved by the 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   48 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Sponsor), allow the study intervention to be used other than as directed by this clinical trial 
protocol, or dispose of  study intervention in any other manner.  
Intervention units are returned by the patient  at each visit. In case of DTP process, the intervention 
units can be returned by the carrier (if defined in the contract).  
Further details will be outlined in the Pharmacy Manual.  
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLINDING   
PRN473 Gel, 5% or placebo will be randomized in a blinded fashion to be administered in each 
patient to 2 separate target lesions (one lesion with PRN473 Gel, 5%, the other with matching 
place bo) during the Blinded Period (Days 1 -14). During the Open -Label Period (Days 15 -42), 
PRN473 will be administered to all AD -affected areas in a thin layer, excluding the scalp, palms, 
soles, and genitals.  
To minimize bias, all safety and efficacy measureme nts will be performed by a study staff 
member who is not involved in the study intervention application during the Blinded Period. If the 
investigational products are applied at the patient’s home or at an external clinic, the local 
tolerability assessment  will be performed by another trained medical professional, different than 
the person administering the study intervention.  
Allocation of lesions on patients to treatment group will proceed through the use of an interactive 
web response system (IWRS) that is accessible 24 hours a day, 365 days a year. A  randomized 
treatment kit number list will be generated centrally by Sanofi for the study interventions. The 
study interventions (PRN473 Gel, 5% or matching placebo) will be packaged in accordance with 
the li st. All  patients will be centrally assigned to randomized study intervention using an 
interactive response technology (IRT). Before the study is initiated, the telephone number and 
call-in directions for the IVRS and/or the log in information and direction s for the IWRS will be 
provided to each site. During the Blinded Period of the study, the treatment each patient receives 
will not be disclosed to the Investigator, trial center personnel, patients, or the Sponsor’s 
representatives on the clinical study te am. Further details for blinding and dispensing of blinded 
treatment are provided in the Pharmacy Manual.   
Access to the randomization code will be limited; all Sponsor personnel (and representatives), and 
site personnel who are directly involved in the co nduct of the trial will be blinded to 
randomization codes.  
The pharmacist or designee will be required to enter or select information that will include, but 
not be limited to; the user ID, and password, patient number, patient year of birth, as well as oth er 
information (as allowed locally). The pharmacist or designee will then be provided with  a patient 
randomization number and treatment assignment. Once patient numbers and  randomization 
numbers have been assigned, they cannot be reassigned. Specific instr uctions will be provided in 
the IWRS trial reference guide.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   49 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Study intervention will be dispensed at the study visits summarized in the Schedule of Activities. 
Returned study intervention should not be re -dispensed to the patients.  
Sponsor safety staff may  unblind the intervention assignment for any patient with an SAE. 
If the SAE requires that an expedited regulatory report be sent to one or more regulatory agencies, 
a copy of the report, identifying the patient’s intervention assignment, may be sent to In vestigators 
in accordance with local regulations and/or Sponsor policy.   
The IRT will be programmed with blind -breaking instructions. In case of an emergency, the 
Investigator has the sole responsibility for determining if unblinding of a patient’s intervention 
assignment is warranted (eg, in case of available antidote). Patient safety must always be the first 
consideration in making such a determination. If the Investigator decides that unblinding is 
warranted, the Investigator should make every eff ort to contact the Sponsor prior to unblinding 
a patient’s intervention assignment unless this could delay emergency treatment of the patient. If  a 
patient’s intervention assignment is unblinded, the Sponsor must be notified within 24 hours after 
breaking the blind. The date and reason that the blind was broken must be recorded in the source 
documentation and case report form, as applicable.  
• In case of an interim analysis, the Sponsor team that will analyze the data would be 
composed of a Medical Monitor, a  biostatistician, a programmer, and a safety designee. 
Only the biostatistician and the programmer will have the access to unblinded individual 
data at the time of the analysis, which will not be provided to other Sponsor team members 
reviewing the data. T hey will keep the randomization schedule in a locked area, which is 
not accessible to the Sponsor’s clinical team and will not disclose the randomization or the 
individual unblinded data before the official opening of the randomization (see 
Section  9.5).  
• The bioanalyst and the pharmacokineticist responsible for the sample analysis and PK 
evaluation will analyze data und er blinded conditions and they will not have access to the 
randomization schedule . 
The Sponsor’s clinical study team, Investigator, Medical Monitor, study personnel, and patients 
are not to make any effort during the Blinded Period to determine which lesio ns are being treated 
with PRN473 Gel, 5%, and which are treated with matching placebo.  
Only in the case of an emergency, when knowledge of the lesion treatment assignment is essential 
for the clinical management or welfare of a specific patient, the Investigator may unblind a 
patient’s lesion treatment assignment. However, prior to any unblinding, the Investigator is 
strongly advised to discuss options with the Medical Monitor, Sponsor, or  appropriate study 
personnel. The Investigator will record in s ource documentation, the date and reason for revealing 
the blinded lesion treatment assignment for that patient and the names and roles of personnel 
unblinded.  
As soon as possible, and without revealing the patient’s lesion treatment assignment (unless 
important to the safety of patients remaining in the study), the Investigator must notify the 
Sponsor if the blind is broken for any reason and the Investigator was unable to contact the 
Sponsor prior to unblinding.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   50 of 100 
Confidential and Proprietary   01-Mar -2022  Final  If the Investigator considers an AE to be of such severity as to require immediate specific 
knowledge of the identity and dose of the relevant product, the Investigator may break the study 
code for that patient.  
6.4 STUDY INTERVENTION C OMPLIANCE   
Study intervention will be administered under site staff or trained medical professional 
supervision during the Blinded Period. The date and time of each dose  administered at the study 
site, at patient’s home, or at external clinic will be recorded. The do se of study intervention and 
patient identification will be confirmed at the time of dosing by site staff or trained medical 
professional other than the person administering the study intervention. Documentation will 
include the lesion identification for t he patient’s 2 target lesions.  
During the Open -Label Period, patients will complete a daily diary to record PRN473 
administered.  
6.5 DOSE MODIFICATION   
No dose modifications will be permitted.  
6.6 CONTINUED ACCESS TO STUDY INTERVENTION A FTER THE END OF 
STUDY   
PRN473 will not be provided to patients after completion of the study.  
6.7 CONCOMITANT THERAPY   
All medications, including over -the-counter (OTC) medications, vitamins, and herbal 
supplements, taken during the 30 days prior to the first study intervention administration will be 
recorded and reviewed by the Investigator  to determine whether the patient is suitable for 
inclusion in the study.  
All medications, and vaccines including OTC medications, vitamins, and herbal supplements, 
taken by patients during the course of the study will be r ecorded in the electronic case report form 
(eCRF) and coded using the most current World Health Organization (WHO) drug dictionary. 
Prior and  concomitant medications will be listed by patient and summarized by anatomical 
therapeutic chemical (ATC) and pref erred name. Any concomitant medication  that the patient 
receives to treat an AE during the study must be recorded along with:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   51 of 100 
Confidential and Proprietary   01-Mar -2022  Final  6.7.1 COVID -19 vacc ination   
To allow for an optimal immune response as well as protection against COVID -19, it is strongly 
recommended that study patients receive their COVID vaccine (per local requirements) a 
minimum of 14 days prior to receiving the first dose of study medication. The safety profile and 
effectiveness of COVID -19 vaccines on people with compromised immune systems or therapies 
that modify or that suppress their immune response, i s not yet established. While vaccination with 
an approved COVID -19 vaccine is widely recommended, this decision should only be made by 
the patient, after discussing with his/her physician as well as the investigator to assess the benefits 
and risks of rece iving a COVID -19 vaccination during this study. If the vaccine is authorized, 
available, and recommended by the local regulatory health authority, it may be administered 
during the study and should be administered according to the label or local health aut hority 
recommendations.  
6.7.2 Prohibited medications   
Excluded medications and treatments with the applicable washout period prior to Baseline are 
listed in Table  5. 
Table  5 - Excluded medications and treatments   
Excluded Medications and Treatments  Washout Period Prior to Baseline  
Rituximab or anti -CD-20-targeted therapies  12 months  
Other biologics including dupilumab and investigational 
biologics  12 weeks or 5 half -lives, whichever is longer  
JAK-inhibitors and investigational JAK -inhibitors  8 weeks or 5 half -lives, whichever is longer  
Systemic treatments that could affect AD (eg,  corticosteroids, 
retinoids, calcineurin inhibitors, hydroxycarbamide 
[hydroxyurea],  methotrexate, cyclosporine, azathioprine, 
hydroxychloroquine, mycophenolate mofetil, or other 
immunosuppressive therapies, or systemic treatment with 
non-sedating antihistamines in a nonstable regimen). Systemic 
treatments with non -sedating antihistamines  in a stable regimen 
are allowed.  4 weeks or 5 half -lives, whichever is longer  
PUVA or NBUVB phototherapy  4 weeks  
Topical products containing urea  1 week  
Sedating antihistamines and doxepin  1 week  
Topical corticosteroids, calcineurin inhibitors, or crisaborole. 
Topical antibacterial medications or products, including soaps, 
dilute bleach baths, or sodium hypochlorite -based products 
anywhere on the body.  4 weeks  
Systemic antibiotics  2 weeks  
Tanning beds, other light emitting devices  4 weeks  
All other investigational drugs  4 weeks or 5 half -lives, whichever is longer  
Any live vaccines  12 weeks   
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   52 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Note:  
Topical antibiotics, topical antihistamines, or any other topical agents  are not permitted to be applied to treated areas.  Only 
study intervention  should be applied to treated areas.  
6.7.3 Permitted medications   
Use of hormonal contraception is allowed prior to and during the study.  
The Medical Monitor should be contacted if there are any questions regarding concomitant 
or prior therapy.  
Non-medicated emollients, moisturizers, and sunscreens will be permitted once daily in  a stable 
regimen as normally used by the patients and applied at least 2 hours after application of 
randomized study intervention to untreated  areas only (topical agents  are not permitted to be 
applied to treated areas; only study intervention should be applied to treated areas).  
6.7.4 Rescue medicine   
Rescue topical medications use will be at the disc retion of the Investigator after discussion with 
the Medical Monitor if the patient is flaring above 14% treatable BSA (excluding scalp, palms, 
soles and genitalia) during the last two weeks of the Open Label Period.  Investigators should 
make every attempt  to conduct efficacy and safety assessments (eg, disease severity scores, safety 
labs) immediately before administering any rescue treatment. An unscheduled visit may be used 
for this, if necessary. Patients who receive rescue treatment will be asked to co ntinue with study 
treatment and procedures.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   53 of 100 
Confidential and Proprietary   01-Mar -2022  Final  7 DISCONTINUATION OF S TUDY INTERVENTION AN D PATIENT 
WITHDRAWAL   
7.1 DISCONTINUATION OF S TUDY INTERVENTION   
7.1.1 Permanent discontinuation   
In rare instances, it may be necessary for a patient to permanently disco ntinue study intervention. 
If study intervention is permanently discontinued, the Investigator must discuss with the Medical 
Monitor to determine if the patient will be asked to continue with PK sample collection 
(if applicable and depending upon the study  day on which the discontinuation occurs), 
and have  early termination safety assessments (Day 43). See the Schedule of Activities in 
Section  1.3. 
Patients  who are enrolled but who do not receive any dose of study intervention will be replaced. 
Patients may be replaced at the discretion of the Sponsor.  
The Investigator/Sponsor must permanently discontinue dosing with stu dy intervention in a 
patient if any of the following patient -level stopping rules are met:   
• Pregnancy will lead to definitive study intervention discontinuation in all cases.  
• Change in compliance with inclusion/exclusion criteria that is clinically releva nt and 
affects patient’s safety.  
• Intake of non -permitted concomitant medications that might affect patient’s safety or 
study assessments/objectives.  
• An allergic reaction, including an anaphylactic reaction, in association with IMP 
administration.  
• Occurrenc e of AEs, that, in the opinion of Investigator/Sponsor, may jeopardize patient’s 
safety or data integrity. These include, but are not limited to  
- Any opportunistic infection, such as TB or other infections whose nature or course 
may suggest an immunocompromised status.  
- Serum ALT >5 × ULN or ALT >3 × ULN and total bilirubin >2 ULN (see 
Section  10.3). 
Any clinic ally significant abnormal laboratory value, as assessed by the investigator, will be 
rechecked for confirmation as soon as possible before making a decision of definitive 
discontinuation of the IMP for the concerned patient.  
Handling of patients after perm anent intervention discontinuation   
Patients will be followed -up according to the study procedures specified in this protocol up to the 
scheduled date of study completion, or up t o recovery or stabilization of any AE to be followed -
up as specified in this protocol, whichever comes last.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   54 of 100 
Confidential and Proprietary   01-Mar -2022  Final  If possible, and after the permanent discontinuation of intervention, the patients will be assessed 
using the procedure normally planned for the la st dosing day with the IMP including a 
pharmacokinetics sample, if appropriate.  
All cases of permanent intervention discontinuation must be recorded by the Investigator in the 
appropriate pages of the eCRF when considered as confirmed.  
7.1.2 Liver chemistry stop ping criteria   
Discontinuation of study intervention for abnormal liver tests is required by the Investigator when 
a patient meets one of the conditions outlined in Appendix 3 ( Section  10.3) or in the presence of 
abnormal liver chemistries not meeting protocol -specified stopping rules if the Inv estigator 
believes that it is in best interest of the patient.  
7.1.3 QTc stopping criteria   
If a clinically significant finding is identified (including, but not limited to changes from baseline 
in QT interval corrected using Fridericia’s formula [QTcF] after  enrollment, the Investigator or 
qualified designee will determine if the patient can con tinue in the study and if any change in 
patient management is needed. This review of the ECG printed at the time of collection must be 
documented. Any new clinically relevant finding should be reported as an AE.  
7.1.4 Hematology stopping criteria   
Discontinuation of study intervention for abnormal neutrophil or platelet tests is required by the 
Investigator when a patient meets one of the conditions outlined in Appendix 3 ( Section  10.3) or 
in the presence of abnormal results not meeting protocol -specified stopping rules if the 
Investigator believes tha t it is in best interest of the patient.  
7.2 PATIENT DISCONTINUAT ION/WITHDRAWAL FROM THE STUDY   
A patient may withdraw from the study at any time at his/her own request or may be withdrawn at 
any time at the discretion of the Investigator  or Sponsor for safety, behavioral, or  compliance 
reasons.  
The patient may be discontinued from the study interven tion but continue in the study for PK 
sample collection (if applicable) and follow -up visits.  
At the time of discontinuation, the patient should have  early termination safety assessments 
(Day  43). See the Schedule of Activities  in Section  1.3. 
If the patient withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collec ted before such a withdrawal of consent.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   55 of 100 
Confidential and Proprietary   01-Mar -2022  Final  If a patient withdraws from the study, he/she may request  destruction of any samples taken 
and not tested, and the Investigator must document this in the site study records.  
7.3 LOST TO FOLLOW -UP  
A patient will be considered lost to follow -up if he or she is unable to be contacted by the study 
site, and the following actions must be taken:  
• The site must attempt to contac t the patient and reschedule the End of Study/Early 
Termination visit as  soon as possible, counsel the patient on the importance of 
participating, and  ascertain whether or not the patient wishes to participate.  
• Before a patient is deemed lost to follow -up, the Investigator or designee must make every 
effort to regain contact with the patient (where possible, 3 telephone calls 
and, if necessary, a  certified letter to the patient's last known mailing address or local 
equivalent methods). These contact attempt s should be documented in the patient’s 
medical record.  
• Should the patient continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
Discontinuation of the study as a whole is described in Secti on 10.1.7 . 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   56 of 100 
Confidential and Proprietary   01-Mar -2022  Final  8 STUDY ASSESSMENTS AN D PROCEDURES   
Study procedures and their timing are summarized in the Schedule of Activities in Section  1.3. 
Protocol waivers or  exemptions are not permitted.  
Immediate safety concerns should be discussed with the Medical Monitor immediately upon 
occurrence or awareness to determine if the patient should continue or discontinue study 
intervention.  
Adherence to the study design requirem ents, including those specified in the Schedule 
of Activities, is essential and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential patients meet 
all eligibility criteria. Patients are permitted to  be re -screened once. The Investigator will maintain 
a screening log to record details of all patients screened and to confirm eligibility or  record 
reasons for screening failure, as applicable.  
Procedures conducted as part of the patient's routine clinica l management (eg, blood count) 
and obtained before signing of the informed consent form (ICF) may be utilized for screening 
or baseline purposes provided the procedures met the protocol -specified criteria and were 
performed within the time frame defined in  the Schedule of Activities.  
The maximum amount of blood collected from each patient over the duration of the study, 
including any extra assessments that may be required, will not exceed 550 mL.  
Repeat or unscheduled samples may be taken for safety reasons  or for technical issues with the 
samples.  
8.1 EFFICACY ASSESSMENTS   
Efficacy assessments will be performed per the Schedule of Assessments in Section  1.3: 
• Lesional PP -NRS is a patient -completed assessment to determine the intensity of lesion 
pruritus.  
• Lesional validated IGA is an Investigator assess ment of the 2  target lesions during the 
Blinded Period and predose at D15 during the Open -Label Period.  
• Eczema Area and Skin Severity Index (EASI) is a validated Investigator -administered 
scoring system used to measure the severity of clinical signs in  AD. 
• Validated Investigator Global Assessment -Atopic Dermatitis (vIGA -AD; Appendix  4, 
Section  10.4.2 ) is an Investigator assessment of the global severity of clinical signs in AD.  
• Lesion TSS (Appendix  4, Section  10.4.3 ) is a scale that rates the severity of each of  4 AD 
symptoms (erythema, induration/papulation, excoriation, and lichenification) on  a 4-point 
scale from 0 (none) to 3 (severe), for a total sco re ranging from 0 to 12.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   57 of 100 
Confidential and Proprietary   01-Mar -2022  Final  • SCORing atopic dermatitis (SCORAD) is a clinical tool used to assess AD by intensity, 
extent, and subjective signs.  
• Peak Pruritus Numeric Rating Scale (PP -NRS) is a patient -completed assessment to 
determine the intensity of peak pr uritus over the previous 24 hours.  
• Patient -Oriented Eczema Measure (POEM) is a validated, patient -derived assessment 
measure for monitoring atopic eczema severity.  
• Dermatology Life Quality Index (DLQI) is a validated, self -administered questionnaire 
design ed to measure the health -related quality of life of adult patients suffering from a  skin 
disease.  
• Estimation of treatable BSA.  
8.2 SAFETY ASSESSMENTS   
Safety will be assessed by means  of application site tolerability assessments ( Appendix 4, 
Section  10.4.1 ), occurrence of AEs, clinical laboratory tes ts (serum chemistry, hematology, 
coagulation, urinalysis), vital signs measurements, 12 -lead ECGs, and physical examinations.  
Planned timepoints for all safety assessments are provided in the Schedule of Activities in 
Sectio n 1.3. 
8.2.1 Physical examinations   
A complete physical examination includes, at a minimum: assessments of the abdomen, chest, ear, 
head and neck, heart, lower limb, upper extremity, lung, musculoskeletal, neurological, rib, skin, 
thoracic vertebra, lumbar spine, and cervical vertebra. Height (only at screening) and weight will 
also be measured and recorded.  
A symptom -directed physical exam is to be performed as clinically indicated at visits when 
a complete examination is not specified.  
Investigators should pay special attention to clinical signs related to previous serious illnesse s. 
8.2.2 Vital signs   
Vital signs will be measured at the timepoints specified in the study schedule with patients resting 
for at least 5 minutes in a supine position. When the time of vital signs measurement coincides 
with a blood draw, the vital signs will be taken before the scheduled blood draw where possible, 
ensuring the blood draw is within the window specified.  
Additional vital sign measurements may be performed at other times if  deemed necessary.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   58 of 100 
Confidential and Proprietary   01-Mar -2022  Final  8.2.3 Electrocardiograms   
A 12 -lead ECG will be performed at the timepoints indicated in the study schedule. Additional 
ECG monitoring may be conducted at other times  as deemed necessary. Refer to Section  7.1.3  for 
QTc withdrawal criteria and any additional QTc readings that may be necessary.  
The ECGs will be performed prior to vital signs with patients in a supine position. Patients must 
remain in this position for at least 5 minutes before the reading is taken. All ECG tracings will be 
reviewed by the Investigator or designee.  
Whe n the time of ECG monitoring coincides with a blood draw, the ECG will be performed 
before the scheduled blood draw while ensuring the blood draw is within the window specified in 
the protocol.  
A repeat ECG can be performed if results are abnormal.  
8.2.4 Clinica l safety laboratory assessments   
See Section  8.2.4.1  for the list of clinical laboratory tests to be performed and the Schedule 
of Activities in Section  1.3 for the timing and frequency.  
The Investigator must review the laboratory report, document this review, and record any 
clinically significant changes occurring during the study as an AE. The laboratory repo rts must be 
filed with the source documents.  
Abnormal laboratory findings associated with the underlying disease are not considered clinically 
significant unless judged by the Investigator to be more severe than expected for the patient's 
condition.  
Any t reatment -emergent abnormal laboratory or ECG result that is clinically significant 
(ie, meeting one or more of the following conditions) should be recorded as a single diagnosis on 
the AE page in the eCRF:  
• Accompanied by clinical symptoms  
• Leading to a chan ge in study intervention (eg, dose modification, interruption, or 
permanent discontinuation)  
• Requiring a change in concomitant therapy (eg, addition of, interruption of, 
discontinuation of, or any other change in a concomitant medication, therapy, 
or treatment)  
Note: Any laboratory or ECG result abnormality fulfilling the criteria for a SAE must be 
reported as such, in addition to being recorded as an AE in the eCRF.  
The laboratory reports must be filed with the source documents.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   59 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Abnormal laboratory finding s associated with the underlying disease are not considered clinically 
significant unless judged by the Investigator to be a more severe variation in patient's disease 
activity than expected.  
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study or within 4 weeks after the last dose of study intervention should be repeated until the 
values return to normal or baseline or are no longer considered clinically significant by the 
Investigator or Medical Monitor.  
If clinically significant values do not return to normal/baseline within a period of time judged 
reasonable by the Investigator, the etiology should be identified, and the Sponsor notified.  
All protocol -required laboratory tests, as define d in Section  8.2.4.1 , must be conducted in 
accordance with the laboratory manual and the Schedule of Activities.  
If laboratory values from non -protocol -specified laboratory tests performed at the institution's 
local laboratory require a change in patient management or are considered clinically significant by 
the Investigator (eg, SAE or AE or dose modification), the res ults must be recorded.  
8.2.4.1  Clinical laboratory tests   
The tests detailed in Table  6 will be performed . Investigators must document their review of each 
laboratory safety report. Additional tests may be performed at any time during the study as 
determined necessary by the Inve stigator or required by local regulations.  
Table  6 - Laboratory tests   
Laboratory Test  Parameters  
Hematology  Hemoglobin  
Hematocrit  
Red blood cell (RBC) count including:  
• reticulocyte %  
Platelet Count  White blood cell (WBC) count with 
differential:  
• Neutrophils  
• Lymphocytes  
• Monocytes  
• Eosinophils  
• Basophils  
Coagulation  International Normalized Ratio (INR)  Activated partial thromboplastin time 
(aPTT)  
Clinical Chemistry a Aspartate aminotransferase (AST)  
Alanine aminotransferase (ALT)  
Gamma -GT (GGT)  
Total and direct bilirubin  
Alkaline phosphatase ( ALP) b 
Creatinine  
Blood urea nitrogen (BUN)/Albumin  
Bicarbonate  
 Sodium  
Potassium  
Calcium  
Chloride  
Phosphate  
Glucose (fasting labs only)  
C-reactive protein  
Creatine kinase (CK) w/h reflex 
Troponin  I >ULN  
Lactate dehydrogenase (LDH)  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   60 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Laboratory Test  Parameters  
Routine Urinalysis  Specific gravity, pH, glucose, protein, occult blood, ketones, urobilinogen, nitrite, 
leukocytes  
Pregnancy testing  Highly sensitive serum (at the Screening visit) or urine (Day 1, Day 29, End of Study 
visits) human chorionic gonadotropin (hCG) pregnancy test (as  needed for women of 
childbearing potential) c 
Other Screening 
Tests  • Follicle -stimulating hormone (as needed in post -menopausal women of 
non-childbearing potential only)  
• Serology (HIV, hepatitis B [surface antigen and core antibodies], hepatitis C  
[anti-HCV antibody confirmed with Hepatitis C RNA])  
• Tuberculosis test (interferon -gamma release assay [IGRA])  
a Details of liver chemistry stopping criteria and required actions and follow -up are given in Section 7.1.2 Liver Chemistry Stopping 
Criteria and Appendix 5  Liver and other safety: suggested actions and follow -up assessments. All events which may indicate severe 
liver injury (possible Hy’s Law) must be reported to Sponsor in an expedited manner (excluding studies of hepatic impairment or 
cirrhosis).  
b If alkali ne phosphatase is elevated, consider fractionating.  
c Local urine testing will be standard for the protocol unless serum testing is required by local regulation or IRB/IEC.  
8.2.5 Pregnancy testing   
• Refer to Section  5.1 Inclusion criteria for pregnancy testing criteria; the Investigator is 
responsible for review of medical history, menstrual history, and recent sexual activity to 
decrease the risk for inclusi on of a female patient with an early undetected pregnancy.  
• Pregnancy testing (urine or serum as required by local regulations) should be conducted at 
study visits accordingly to the SoA ( Section  1.3). 
• Pregnancy testing (urine or serum as required by local regulations) must be conducted 
corresponding with the time frame for female patient contraception in Section  5.1 
Inclusion criteria.  
• Additional serum or urine pregnancy tests may be performed, as determined necessary by 
the investigato r or required by local regulation, to establish the absence of pregnancy at 
any time during the patient’s participation in the study.  
8.2.6 Local Cutaneous Tolerability   
Grading of appl ication site local tolerability symptoms will be recorded using the grading scale 
(Appendix  4, Section  10.4.1 ) following each dosing during the blinded period. Each target lesion 
will be graded within approximately 30 minutes after dosing by site staff or trained medical 
professional and a record of t he worst symptom grade during time period will be recorded. During 
the Open Label period symptom grading will record worst symptom observed on the lesional 
areas treated within approximately 30 min after dosing.  
8.3 ADVERSE EVENTS, SERI OUS ADVERSE EVENTS A ND O THER SAFETY 
REPORTING   
The definitions of AEs and SAEs can be found in Section  8.3.1 . 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   61 of 100 
Confidential and Proprietary   01-Mar -2022  Final  AE will be reported by the patient (or, when appropriate, by a caregiver, surrogate, or the patient’s 
legally authorized representative).  
The Investigator and any qualified designees are res ponsible for detecting, documenting, 
and recording events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study intervention or study 
procedures, or that caused the patient to  discontinue the study intervention (see Section  7). 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures 
for completing and transmitting SAE reports are provided in Section  8.3.1 . 
8.3.1 AEs and SAEs: Definitions and procedures for recording, evaluating, follow -up, and 
reporting   
8.3.1.1  Definition of AE   
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether or not considered related 
to the study intervention.  
• NOTE: An AE can therefore be any unf avorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention.  
Events Meeting  the AE definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the Investigator (ie, not related to progression of underlying 
disease):  
- Symptomatic and/or  
- Requiring either corrective treatment or consultation, and/or  
- Leading to study intervention discontinuation or modification of dosing, and/or  
- Fulfilling a seriousness criterion, a nd/or  
• Exacerbation of a chronic or intermittent pre -existing condition including either 
an increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention administration even though 
it may have been p resent before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   62 of 100 
Confidential and Proprietary   01-Mar -2022  Final  • “Lack of effic acy” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be re ported as AE or SAE if they fulfill the definition of an AE or SAE.  
Events NOT Meeting the AE definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
Investigator to be more severe than expected for the patient’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the patient’s  
condition.  
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social 
and/or  convenience admission to a hospital).  
• Anticipated day-to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
8.3.1.2  Definition of SAE   
An SAE is defined as any AE  that, at any dose:  
a) Results in death  
b) Is life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the 
patient was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
c) Requires inpatient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the patient has been admitted (usually involving at 
least an overnight stay) at the h ospital or emergency ward for observation and/or  treatment 
that would not have been appropriate in the physician’s office or  outpatient setting. 
Complications that occur during hospitalization are AEs. If  a complication prolongs 
hospitalization or fulfills  any other serious criteria, the  event  is serious. When in doubt as 
to whether “hospitalization” occurred or was necessary, the AE should be considered 
serious.  
Hospitalization for elective treatment of a pre -existing condition that did not worsen from 
baseline is not considered an AE.  
d) Results in persistent or significant disability/incapacity  
- The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   63 of 100 
Confidential and Proprietary   01-Mar -2022  Final  - This definition is not intended to include experiences of r elatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruptio n. 
e) Is a congenital anomaly/birth defect  
f) Other situations:  
- Medical or scientific judgment should be exercised by the Investigator in deciding 
whether SAE reporting is appropriate in other situations such as significant medical 
events that may jeopardize the  patient or may require medical or surgical intervention 
to prevent one of the other outcomes listed in the above definition. These  events 
should usually be considered serious.  
Note: The following list of medically important events is intended to serve as 
a guideline for determining which condition has to be considered as a medically 
important event. The list is not intended to be exhaustive:  
- Intensive treatment in an emergency room or at home for:  
- Allergic bronchospasm    
- Blood dyscrasias (ie, agranulocyt osis, aplastic anemia, bone marrow aplasia, 
myelodysplasia, pancytopenia, etc)  
- Convulsions (seizures, epilepsy, epileptic fit, absence, etc)  
- Development of drug dependence or drug abuse  
- Suicide attempt or any event suggestive of suicidality  
- Syncope, loss of consciousness (except if documented as a consequence of blood 
sampling)  
- Bullous cutaneous eruptions    
8.3.1.3  Recording and follow -up of AE and/or SAE   
AE and SAE recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all  
documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event.  
• The Investigator will then record all relevant AE/SAE  information.  
• It is not acceptable for the Investigator to send photocopies of the patient’s medical 
records to the Sponsor’s representative in lieu of completion of the required form.  
• There may be instances when copies of medical records for certain cases  are requested by 
the Sponsor’s representative. In this case, all patient identifiers, with the exception of the 
patient number, will be redacted on the copies of the medical records before submission to 
the Sponsor’s representative.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   64 of 100 
Confidential and Proprietary   01-Mar -2022  Final  • The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The Investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by the patient, causing minimal discomfort and not 
interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort to interfere with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE. “Severe” is a category used fo r rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.  
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe.  
Assessment o f Causality  
• The Investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, evidence, 
and/or  arguments to suggest a causal relationship, rather than that a relationship cannot 
be ruled out.  
• The Investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the tem poral relationship of the event to study intervention 
administration will be considered and investigated.  
• The Investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.  
• For each  AE/SAE, the Investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in th e initial report to the Sponsor . However, it is very important 
that the Investigator always make an assessment of causality for every event before 
the initial transmission of the SAE data to the Sponsor . 
• The Investigator may change his/her opinion of causa lity in light of follow -up information 
and send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   65 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Follow -up of AEs and SAEs  
• The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the Sponsor’s 
representative to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• If a patient dies during participation in the study or during a recognized follow -up period, 
the In vestigator will provide the Sponsor with a copy of any post -mortem findings 
including histopathology.  
• New or updated information will be recorded in the originally submitted documents.  
• The Investigator will submit any updated SAE data to the Sponsor  within  24 hours of 
receipt of the information.  
8.3.1.4  Reporting of SAEs   
SAE reporting to the Sponsor via an electronic data collection tool  
• The primary mechanism for reporting an SAE to  the Sponsor’s representative will be the 
electronic data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection 
tool (see next section) to report the event within 24 hours.  
• The site will enter the SA E data into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data.  
• If a site receives a r eport of a new SAE from a study patient or receives updated data on 
a previously reported SAE after the electronic data collection tool has been taken off -line, 
then the site can report this information on a paper SAE form (see next section) or to the 
Spon sor’s representative by telephone.  
• Contacts for SAE reporting can be found in the study reference manual . 
SAE reporting to the Sponsor via paper data collection tool  
• Facsimile transmission of the SAE paper data collection tool is the preferred method to 
transmit this information to the Sponsor’s representative.  
• In rare circumstances and in the absence of facsimile equipment, notification by telephone 
is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier 
service.  
• Initial  notification via telephone does not replace the need for the Investigator to complete 
and sign the SAE data collection tool within the designated reporting time frames . 
• Contacts for SAE reporting can be found in the study reference manual . 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   66 of 100 
Confidential and Proprietary   01-Mar -2022  Final  8.3.2 Time period and  frequency for collecting AE and SAE information   
All AEs (serious or nonserious) will be collected from the signing of the ICF until the follow -up 
visit at the timepoints specifi ed in the Schedule of Activities ( Section  1.3). 
All SAEs will be recorded and reported to the Sponsor or designee immediately and  under no 
circumstance should this exceed 24 hours, as indicated in Section  8.3.1 . The Investigator will 
submit any updated SAE data to the Sponsor within 24  hours of it being available.  
Investigators are not obligated to actively seek information on AEs or SAEs after conclusion 
of the study  participation. However, if the Investigator learns of any SAE, including a death, 
at any time after a patient has been discharged from the study, and he/she considers the event 
to be reasonably related to the study intervention or study participation, the  Investigator must 
promptly notify the Sponsor.  
8.3.3 Method of detecting AEs and SAEs   
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leadi ng verbal questioning of the patient is the preferred method to inquire about AE 
occurrences.  
8.3.4 Follow -up of AEs and SAEs   
After the initial AE /SAE report, the Investigator is requ ired to proactively follow each patient at 
subsequent visits/contacts. At the pre -specified study end -date, all SAEs, and will be followed 
until resolution, stabilization, the event is otherwise explained, or the patient is lost to follow -up 
(as defined in  Section  7.3). Further information on follow -up procedures is provided in 
Section  8.3.1 . 
8.3.5 Regulatory reporting requirements for SAEs   
• Prompt notification by  the Investigator to the Sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of patients and the safety of 
a study intervention under clinical investigation are met.  
• The Sponsor has a legal responsibilit y to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the r egulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC), and Investigators.  
• Serious adverse events that are considered expected will be specified in the reference 
safety information in the Investigator’s Brochure.  
• Invest igator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regulatory requirements and Sponsor policy and 
forwarded to Investigators as necessary.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   67 of 100 
Confidential and Proprietary   01-Mar -2022  Final  • An Investigator who receives an Investigator safet y report describing an SAE, SUSAR, or 
any other specific safety information (eg, summary or listing of SAEs) from the Sponsor 
will review and then file it along with the Investigator’s Brochure and will notify the 
IRB/IEC, if appropriate according to local  requirements. It is the responsibility of the 
Sponsor to assess whether an event meets the criteria for a SUSAR, and therefore, is 
expedited to regulatory authorities.  
8.3.6 Pregnancy   
• Details of all pregnancies in female patients and female partners of male patients  will be 
collected after the start of study intervention and through 30 days after the final dose of the 
study intervention.  
• If a pregnancy is reported, the Investigator will record pregnancy information on the 
appropriate form and submit it to the Sponsor within 24 hours of learning of the female 
patient or female partner of male patient (after obtaining the necessary signed informed 
consent from the female partner) pregn ancy.  
- Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported as 
such 
• The patient /pregnant female partner  will be followed to determine the outcome of  the 
pregnancy. The Investigator will collect follow -up information on the patient/pregnant 
female partner and the neonate, and the information will be forwarded to the Sponsor.  
• Any post -study pregnancy -related SAE considered reasonably related to the stud y 
intervention by the Investigator will be reported to the Sponsor as described in 
Section  8.3.5 . While the Investiga tor is not obligated to actively seek this information in 
former study patient/pregnant female partner, he or she may learn of an SAE through 
spontaneous reporting.  
• Any female patient who becomes pregnant while participating in the study will 
discontinue s tudy intervention or be withdrawn from the study.  
8.3.7 Expedited reporting requirements   
The AEs below will be recorded and reported to the Sponsor or designee immediately and under 
no circumstance should this exceed 24 hours. Such events may require further investigation in 
order to characterize and understand them.  
• Symptomatic overdose (serious or nonserious) with study intervention  
- An overdose (accidental or intentional) with the study intervention is an event 
suspected by the Investigator or spontaneously notified by the patient (not based on 
study intervention tube weight) and defined as greater than twice the intended dose 
within the intended therapeutic interval, adjusted accor ding to the tested drug.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   68 of 100 
Confidential and Proprietary   01-Mar -2022  Final  • Elevation of liver enzymes as below (see Appendix 3, Section  10.3 for flow chart of 
required  activities)  
- ALT >3 × upper limit of normal (ULN)  
• If a pregnancy is reported, the Investigator will record pregnancy information on the 
appropriate form and submit it to the Sponsor within 24 hours of learning of the pregnancy 
(see Section  8.3.6 ). 
8.3.8 Guidelines for reporting product complaints   
Any defect in the study intervention must be reported as soon as possible by the Investigator to 
the monitoring team that will complete a product complaint form within required timelines.  
Appropriate information (eg, samples, labels, or documents like pict ures or photocopies) 
related  to product identification and to the potential deficiencies may need to be gathered. 
The Investigator will assess whether or not the quality issue has to be reported together with 
an AE or  SAE.  
8.4 PHARMACOKINETICS   
Blood samples of approximately 4 mL per sample will be collected for measurement of plasma 
concentrations of PRN473 as specified in the Schedule of Activities in Section  1.3. Venipuncture 
should not occur within a treated area.  
Instructions for the collection and handling of biological samples will be provided by the Sponsor. 
The actual date and time (24 -hour clock time) of each sample will be recorded.  
The actual collection time of each sample must be recorded in the source data documentation, and 
in the eCRF. The allowed time deviation window before a deviatio n is recorded for blood sample 
collection post dose is 15 minutes for timepoints up to and including 6 hours postdose; predose 
samples should be collected within 30 minutes prior to the next application of study intervention .  
Samples will be used to evalu ate the PK of PRN473. Samples collected for analyses of PRN473 
plasma concentration may also be used to evaluate safety or efficacy aspects related to concerns 
arising during or after the study. Pharmacokinetic endpoints are listed in Section  3. 
After the blood samples are analyzed for plasma PRN473 concentrations, any residual samples 
may be used for analysis such as me tabolite profiling and identification, interacting drug 
concentration measurements, ex vivo protein binding, or development of PK assays. Residual PK 
samples will be destroyed within 1 month of withdrawal of consent. Residual PK samples will be 
stored for 5 years after the final Clinical Study Report, at which point they will be destroyed.  
Genetic analyses will not be performed on these samples. Patient confidentiality will be 
maintained.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   69 of 100 
Confidential and Proprietary   01-Mar -2022  Final  8.5 GENETICS AND/OR PHAR MACOGENOMICS   
Genetics and/or pharmacogenomics will not be evaluated in this study.  
8.6 BIOMARKERS   
Changes in protein  and RNA expression, lymphocyte infiltration, and  epidermal thickness 
following treatment with PRN473 will be evaluated using blood samples, skin tape stripping and 
skin biopsy.  
Changes in blood biomarkers will be assessed following treatment with PRN473.  
Future research may help further the understanding of disease subtypes, disease biology, related 
conditions, drug response and toxicity, and can help identify new drug targets or biomarkers that 
predict participant  response to treatment. Therefore, data an d biological samples will be stored 
and used for future research when consented to by participant s (see Section  10.1.3 ) unless 
prohibited by local laws or IRBs/IECs (in such case, consent for future use of sample will not be 
included in the local ICF).  
For patients who consent to the storage and use of their data and remaining and/or extra clinical 
samples, data and samples may be used after the study ends for future research related either to 
the drug, the mechanism of action, and the disease or its associated conditions. Such research may 
include, but is not limited to, performing assessments on DNA, RNA, proteins, or metabolites. If 
future research on genetic material is performed, this will also be limited to the purpose of 
addressing research questions related to the drug, the mechanism of action, the disease, or its 
associated conditions.  
In the event future rese arch is conducted  for other purposes, the study patients will be informed of 
those purposes and will be given means to object to those research projects.  
Data and samples will be used in compliance with the information provided to patients in the ICF.  
All study patient data and samples will be coded such that no patient direct identifiers will be 
linked to them. Coded data and samples may be transferred to a Sponsor site (or a subcontractor 
site), which may be located  outside of the country where the study is conducted. The Sponsor 
adopts safeguards for protecting patient confidentiality and personal data (see Section  10.1.4 ). 
The samples will be stored for a maximum of 15 years after the end of the study. Any samples 
remaining at the end of retention period will be destroyed. If a patient requests destruction of 
his/her samples before the end of the retention period, the Investigator must notify the Sponsor (or 
its contract organization) in writing. In such case, samples will be destroyed, and related coded 
data will be anonymized unless otherwise required by applicable laws.  
Study patient coded data will be stored for future research for up to 25 years after the end of the 
study. If data are still considered of important scientific value after this period, coded data already 
available will be anonymized unless otherwise requir ed by applicable laws (the same will apply to 
the data of a study patient who has requested the destruction of his/her samples).  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   70 of 100 
Confidential and Proprietary   01-Mar -2022  Final  The patient’s coded data sets provided to researchers for a specific research project will be 
available to the researchers for a maximum of 2 years after the end of their specific project (end  of 
project is defined by publication of the results or finalization of the future research project report).  
8.7 IMMUNOGENICITY ASSES SMENTS   
Immunogenicity assessments  will not be performed as part of this study.  
8.8 HEALTH ECONOMICS OR MEDICAL RESOURCE UTI LIZATION AND 
HEALTH ECONOMICS   
Health Economics or Medical  Resource Utilization and Health Economics parameters are not 
evaluated in this study.  
8.9 LESION PHOTOGRAPHY   
Photographs will be used to document change/i mprovement in lesions, and to document biopsy 
location as detailed in the lab manual and will not be used to evaluate AEs.  
For the Blinded Period, photographs will be taken of the 2 target lesions at predose Baseline  and 
Day 8. For the Open -Label  Period, photographs of the 2 target lesions will be taken predose at 
Day 15, Day 29 and at Day 43. 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   71 of 100 
Confidential and Proprietary   01-Mar -2022  Final  9 STATISTICAL CONSIDER ATIONS   
9.1 STATISTICAL HYPOTHES ES  
No statistical hypotheses will be tested.  
9.2 SAMPLE SIZE DETERMIN ATION   
No sample size calculations wer e performed due to the exploratory nature of this study.  
The sample size of up to 40 for this study with patients receiving both PRN473 Gel, 5% 
and placebo is based upon empirical clinical consideration. The sample size is considered 
adequate to evaluate t he safety, tolerability, and PK of topically administered PRN473.  
This study is signal seeking and  neither aimed nor powered to provide formal inferential statistical 
analyses.  
9.3 ANALYSIS SETS   
For the purposes of analysis, the following analysis sets are defined:  
Table  7 - Analysis sets   
Patient Analysis Set  Description  
Screened  All patients who signed the ICF.  
Enrolled/Randomized  All patients from the screened population who have been allocated to 
a randomized intervention by IRT regardless of whether the intervention was 
received.  
Safety  All randomized patients who receive any amount of study intervention 
(PRN473 or  placebo) will be included in the Safety population. The Safety 
population will be based on the intervention actually received and will be used 
for the summaries of all safety a ssessments.  
Pharmacokinetic  All patients who received any amount of active study intervention (PRN473) 
and have at least one PK sample taken will be included in the PK population. 
The PK population will be used for the summaries of all PK data.  
ITT All randomized patients who did actually receive at least 1 complete dose of 
study intervention with at least 1  post-study intervention administration 
measurement, with available efficacy.  
Efficacy  All randomized patients who did actually receive at least 80%  of prescribed 
study intervention in the Blinded Period and/or at least 80% of prescribed 
study intervention in the Open -Label Period and with at least 1  post-study 
intervention administration efficacy measurement in the corresponding period, 
Patients will  be analyzed according to the intervention they actually received.  
Biomarker  All patients with no important deviations impacting Biomarker measurements, 
for whom the Biomarker data are considered sufficient and  interpretable.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   72 of 100 
Confidential and Proprietary   01-Mar -2022  Final  9.4 STATISTICAL ANALYSES   
The Statistical Analysis Plan (SAP) will be issued prior to database lock and will include a  more 
technical and detailed description of the statistical analyses and the tables and  graphs described in 
this section.  
This section is a summary of the planned statistical analyses of the key endpoints.  
9.4.1 General considerations   
In general, descriptive statistics (ie, arithmetic mean, standard deviation [SD], median, minimum, 
and maximum ) will be calculated for continuous valued measurements, for each treatment where 
appropriate. Changes and percent changes from baseline to each applicable scheduled post -
baseline timepoint will similarly be summarized by treatment where appropriate. Frequen cy 
summaries (ie, count and  percentage of observations at each category level) will be applied for 
categorical data for each scheduled timepoint by treatment where appropriate.  
9.4.2 Endpoints   
Endpoints are listed in  Table  3. 
9.4.3 Analysis of efficacy data   
Efficacy analyses will be based on the Efficacy population. A patient will be considered evaluable 
per endpoint and study period, if they receive at least 80% of prescribed study intervention in that 
period and have a post -baseline assessment of the corres ponding endpoint for that period (ie,  after 
Day 1 or after Day 15).  
Where appropriate, supplemental analyses will be presented excluding observations after 
administration of rescue medication. Imputation would then be performed for missing 
observations inc luding those due to withdrawal due to lack of efficacy, as will be specified in the 
SAP.  
Efficacy analyses will be an early explorative assessment and performed without the aim of 
formal inferential statistics. No adjustment will be made for multiple analyses.  
Treatment differences or ratios will be assessed for PRN473 Gel, 5% versus placebo,  mainly at 
Day 15. Data will be presented by treatment for the Blinded Period where assessed per lesion, and 
overall otherwise, as well as for the Open -Label Period.  
9.4.3.1  Lesion Total Sign Score (TSS)   
Main comparison for TSS will be the comparison between PRN473 Gel, 5% and placebo for 
change from Baseline to Day 15.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   73 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Change in TSS will be analyzed with a linear mixed effects model with fixed terms for treatment 
and with baseline TSS as  a covariate  
Change in TSS = baseline TSS + treatment + error  
and with an unstructured matrix of treatment variances and covariance for patient, using SAS Proc 
Mixed®. In case of convergence problems, other variance -covariance structures will be explored. 
Baseline TSS will be defined as the mean TSS from the two treated lesions at baseline.  
The 95% Confidence Interval (CI) for the treatments effect will be obtained for the difference 
between treatment means within the linear mixed effects model framework. Additionally, 
80% CIs will be derived and presented.  
Descriptive statistics and graphical displays will be provided for all timepoints.  
Additional explorative analyses may be performed.  
9.4.3.2  Further efficacy endpoints during the blinded period   
Further efficacy endpoints during the blinded period will be summarized per treatment 
and timepoint:  
• Change from Baseline in daily lesional PP -NRS score up to Day 15  
• Change from Baseline in lesi onal validated IGA score at Days  8 and  15 
• Lesional validated IGA response (proportion of patients with a  validated IGA score of 0 or 
1 and ≥2-grade improvement from Baseline) at Days 8 and 15  
Further explorative analyses may be performed.  
9.4.3.3  Eczema Area and S kin Severity Index (EASI)   
The following endpoints will be derived and analysed:  
• Change from Baseline in EASI at Days 29 and  43 
• Change from Day 15 in EASI to Days 29 and  43 
• Proportion of patients with EASI 50, EASI 75, and  EASI  90 from Day 15 to Days 29 
and 43 
Changes in EASI from Day 15 to Day 29 and to Day 43 will be analyzed descriptively. 
Estimations with 95% and 80% CIs may be derived. Descriptive statistics and graphica l displays 
will be provided per timepoint.  
Frequency tables will be provided for EASI 50, EASI 75, and EASI 90.  
Further explorative analyses may be performed.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   74 of 100 
Confidential and Proprietary   01-Mar -2022  Final  9.4.3.4  Validated Investigator Global Assessment -Atopic Dermatitis (vIGA -AD)  
The proportion of patients achieving  at least 2 grade reduction in vIGA -AD to clear (vIGA -AD 0) 
or almost clear (vIGA -AD 1) from Day 15 to Days 29 and 43 will be summarized.  
Further explorative analyses may be performed.  
9.4.3.5  Further efficacy endpoints during the open -label period   
Further e fficacy endpoints during the open label period will be summarize d per timepoint:  
• Change from Baseline in TSS for the 2 target lesions at Days 29 and 43.  
• Change in PP -NRS from Day 15 to Days 29 and 43  
• Proportion of patients achieving at least 3 -point reduction from Day 15 in PP -NRS at 
Days  29 and  43 
• Proportion of patien ts achieving at least a 4 -point reduction from Day 15 in PP -NRS 
at Days  29 and  43 
• Change from Day 15 in weekly mean of PP -NRS at Days 29 and  43 
• Change from Day 15 in SCORAD at Days 29 and 43  
• Change from Day 15 in percentage of treatable BSA at Days 29 and  43  
• Change from Baseline in POEM at Days 15, 29, and  43 
• Change from Baseline in DLQI at Days 15, 29, and 43  
9.4.4 Analysis of safety data   
The safety evaluation will be based upon the review of the individual values (clinically significant 
abnormalities), descriptive statistics (summary tables, figures) and, if needed, on  statistical 
analysis (appropriate estimations, confi dence intervals). No statistical significance tests will be 
performed on safety data.  
Potentially clinically significant abnormality (PCSA) values are defined as abnormal values 
considered medically important by the Sponsor, according to predefined criteri a/thresholds based 
on literature reviews and defined by the Sponsor for clinical laboratory tests, vital signs, and  ECG 
parameters.  
All the safety analyses will be performed based on the safety population. Where appropriate, 
supplemental analyses will be p resented excluding observations after administration of rescue 
medication.  
For all safety data variables, the following observation periods are defined and used for 
classification of AEs, determination of on -treatment PCSA values, and the last on -treatment  value 
for laboratory and vital sign parameters:  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   75 of 100 
Confidential and Proprietary   01-Mar -2022  Final  • The pre -treatment period is defined as the time between informed consent signature 
and the first study intervention administration.  
• The treatment -emergent period is defined as the time from the first study i ntervention 
administration through the End of Study visit.  
• The post treatment period is defined as the time starting after the treatment -emergent 
period.  
9.4.4.1  Assignment to treatment and study phase   
Safety data will be assigned to study phase as following:  
• Blinded Period, if the TEAE onset was between the first administration (Day 1) of any 
study intervention in the Blinded Period and the first administration of study intervention 
(PRN473 Gel, 5%) in the Open -Label Period (scheduled  Day 15).  
• Open -Label Period, if the TEAE onset was after the first administration of study 
intervention (PRN473 Gel, 5%) in the Open -Label Period (scheduled Day 15).  
Adverse events which are possibly related to study intervention and have onset date after the first 
dose of PRN473 will be considered possibly related to PRN473, unless they are documented as 
possibly related to the study intervention formulation of the placebo -treated lesion and not 
possi bly related to the study intervention formulation of the PRN473 Gel, 5% -treated lesion.  
Table  8 - Safety analysis   
Safety Measures  Statistical Analysis Methods  
Adverse events  
• AEs  
• TEAEs  
• SAEs  
• AEs leading to study intervention or study 
discontinuation  
• AEs leading to death  
• PCSAs  
 Treatment -emergent adverse event incidence tables 
will be presented by System Organ Class, high -level 
group term, high -level term, and Preferred Term for 
each study period and overall, showing the number (n) 
and percentage (%) of patients experiencing a TEAE.  
Multiple occurrences of the same event in the same 
patient will be counted only once in the tables. The 
denominato r for computation of percentages will be the 
corresponding safety population. In addition, TEAEs 
will be described according to maximum intensity 
and relation to the study intervention.  
Adverse events that occur outside the treatment 
emergent period will be listed separately.  
Proportion of patients with at least 1  TEAE, 
treatment -emergent SAE, TEAE leading to death, 
and TEAE leading to definitive treatment 
discontinuation will be tabulated by study period 
and overall.  
The incidence of PCSAs occurring duri ng the TE 
period will be summarized overall and by baseline 
status.  
Abbreviations: AE  = adverse event; PCSA  = potentially clinically significant abnormality; SAE  = serious adverse event; 
TEAE  = treatment -emergent adverse event.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   76 of 100 
Confidential and Proprietary   01-Mar -2022  Final  9.4.4.2  Analyses of adverse events   
Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA; 
version in use by the Sponsor at the time of database lock). Clinical judgment shoul d be used to 
determine the severity of AEs.  
Adverse events will be classified into predefined standard categories according to chronological 
criteria:  
• Pre-treatment AEs: AEs that occurred, worsened, or became serious during the 
pre-treatment period.  
• Treatm ent-emergent AEs: AEs that occurred, worsened, or became serious during the TE 
period.  
• Post-treatment AEs: AEs that occurred, worsened, or became serious during the 
post-treatment period.  
If the onset date (or time) of an AE (occurrence, worsening, or beco ming serious) is incomplete or 
missing, the AE will be considered as a TEAE unless a partial date (or time) shows it as a pre - or 
post-treatment event.  
All AEs reported in the study will be listed, sorted by patient, onset date, and time.  
Main summary will  be per study period (Blinded Period, Open -Label Period) and overall.  
If selected TEAEs from the Blinded Period can be clearly assigned to one of the study 
intervention treated lesions, they may be presented additionally assigned to the treatment of the 
corresponding lesion.  
Any TEAEs which may occur between the first administration of placebo and the first 
administration of PRN473 Gel, 5% will be presented separately.  
9.4.4.3  Local cutaneous tolerability   
Signs of local cutaneous intolerability as incidence and severity of application -site 
burning/stinging, itching, and erythema will be summarized for the Blinded Period by treatment 
(PRN473 Gel, 5% or placebo) and overall for the open -label phase.  
9.4.4.4  Extent of study treatment exposure and compliance   
A summary table presenting the exposure of treatment (ie, the number of days or weeks 
of administration) will be provided by treatment group for the Safety population.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   77 of 100 
Confidential and Proprietary   01-Mar -2022  Final  9.4.4.5  Laboratory data   
Descriptive statistics of all laboratory data variables (values and changes from Baseline) will be 
calculat ed for each scheduled visit (Baseline and post -Baseline timepoints). Frequencies for 
PCSAs will be presented.  
9.4.4.6  Vital signs   
Descriptive statistics of all vital signs variables (val ues and changes from Baseline) will be 
calculated for each scheduled visit (Baseline and post -Baseline timepoints). Frequencies for 
PCSAs will be presented.  
9.4.4.7  Electrocardiogram   
Descriptive statistics (including number, mean, median, standard deviation, minimum, 
and maximum) of all ECG variables (values and changes from Baseline), will be calculated for 
each visit (Baseline and post -Baseline timepoints). Frequencies for PCSAs will  be presented.  
9.4.5 Analysis of pharmacokinetic data   
Due to the negligible amount of systemic absorption observed following topical administration of 
PRN473 Gel to healthy subjects, t he PK sampling scheme is designed to be semi -sparse. For  that 
reason, plasma PRN473 concentrations, but not plasma PRN473 PK parameters, will be reported.  
9.4.5.1  Pharmacokinetic parameters   
Not applicable.  
9.4.5.2  Analysis of pharmacokinetic concentrations   
For PK concentrations, the arithmetic mean, SD, median, minimum, maximum, percent 
coefficient of variation (CV%), g eometric mean, geometric coefficient of variation (geometric 
CV%), and the number of observations below the limit of quantification (BLQ) values will be 
presented by timepoint. For the purpose of calculating summary statistics, plasma concentrations 
(and a pplicable metabolites) that are BLQ will be set to 0 if taken before first study intervention , 
and to missing elsewhere. Additional analyses will be performed as deemed necessary upon 
review of the data.  
Graphical displays  of concentrations over time may also be presented.   
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   78 of 100 
Confidential and Proprietary   01-Mar -2022  Final  9.4.6 Other analyses   
9.4.6.1  Biomarkers   
Changes from baseline in biomarkers using blood sampl es, skin tape stripping and skin biopsy 
will be analyzed between treatments within patients. Statistical analyses of biomarkers will be 
exploratory in nature and will be detailed in a Biomarker SAP.  
9.4.6.2  Further exploratory endpoint(s)   
Details on the analysis of further endpoints  will be provided in the SAP.  
9.5 INTERIM ANALYSIS   
An interim analysis for internal decision making may be implemented with approximately 25 or 
more of the planned participants who have completed the Blinded Period (Day 14). Available data 
of the Open Label Period may be included in the analysis as appropr iate. The outcome is meant 
for internal decision making and may lead to early termination of the study in case of unfavorable 
signals or continuation without any changes.  
The Sponsor team that will analyze the data will include : a Medical Monitor, a biosta tistician, a 
programmer, and a safety designee. Only the biostatistician and the programmer will have the 
access to unblinded individual data at the time of the analysis, which will not be provided to other 
Sponsor team members reviewing the data. Details of the analysis will be specified in a dedicated 
analysis plan, and results will be provided in a restricted way following a dissemination plan, 
issued before any treatment code release for the analysis established upfront before the 
unblinding. The blindi ng will be preserved notably toward the Investigator, other site staff 
involved in the conduct of the trial, and participants.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   79 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS   
10.1 APPENDIX 1: REGULATO RY, ETHICAL, AND STU DY OVERSIGHT 
CONSIDERATIONS   
10.1.1  Regulatory and ethical considerations   
This study will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the 
Declaration  of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines.  
• Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) 
Guidelines.  
• Applicable laws and regulations.  
The pr otocol, protocol amendments, ICF, Investigator’s Brochure, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and 
approved by the IRB/IEC before the study is initiated.  
Any amendments to the p rotocol will require IRB/IEC approval before implementation of  changes 
made to the study design, except for changes necessary to eliminate an  immediate hazard to study 
patients.  
Protocols and any substantial amendments to the protocol will require health a uthority approval 
prior to initiation except for changes necessary to eliminate an immediate hazard to study patients.  
The Investigator will be responsible for the following:  
• Providing written summaries of the status of the study to the IRB/IEC annually or  more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC.  
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
IRB/IEC procedures.  
• Providing oversight of the conduct of the study  at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, and all other applicable local regulations.  
10.1.2  Financial disclosure   
Investigators and sub -investig ators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   80 of 100 
Confidential and Proprietary   01-Mar -2022  Final  responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3  Informed consent process   
The Investigator  or his/her representative will explain the nature of the study to the patient 
and answer all questions regarding the study.  
Patients must be informed that their participation is voluntary. Patients  will be required to sign 
a statement of informed consent that meets the requirements of 21 CFR 50, local regulations, ICH 
guidelines, Health Insurance Portability and Accountability Act (HIPAA) requirements, where 
applicable, and the IRB/IEC or study center.  
The medical record must include a statement that writt en informed consent was obtained before 
the patient was enrolled in the study and the date the written consent was obtained. The authorized 
person obtaining the informed consent must also sign the ICF.  
Patients must be re -consented to the most current vers ion of the ICF(s) during their participation 
in the study.  
A copy of the signed ICF must be provided to the patient . 
Patients who are rescreened are required to sign a new ICF.  
10.1.4  Data protection   
Patients will be assigned a unique identifier by the Sponsor. Any patient records or  datasets that 
are transferred to the Sponsor will contain the identifier only; patient names or any information 
which would make the patient identifiable wi ll not be transferred.  
The patient must be informed that his/her personal study -related data will be used by the Sponsor 
in accordance with local data protection law. The level of disclosure must also be explained to the 
patient, who will be required to gi ve consent for data to be used as described in  the informed 
consent.  
The patient must be informed that his/her medical records may be examined by Clinical Quality 
Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate 
IRB/IEC members, and by inspectors from regulatory authorities.  
10.1.5  Data quality assurance   
All patient data relating to the study will be recorded on printed or electronic eCRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The Investigator is 
responsible for verifying that data entries are accurate and correct by physically or electronically 
signing the eCRF.  
Guidance on completion of eCRFs will be provided.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   81 of 100 
Confidential and Proprietary   01-Mar -2022  Final  The Investigator must permit study -related monitoring, audits, IRB/IEC review, and  regulatory 
agency inspections and provide direct access to source data documents.  
Quality tolerance limits (QTLs) may be used  to identify systematic issues that can impact patient 
safety and/or reliability of study results. Data quality parameters will be monitored during the 
study and important deviations tracked, and remedial actions taken will be summarized in the 
clinical study report.  
Monitoring details descr ibing strategy (eg, risk -based initiatives in operations and  quality such as 
Risk Management and Mitigation Strategies and Analytical Risk -Based Monitoring), methods, 
responsibilities and requirements, including handling of noncompliance issues and monitor ing 
techniques (central, remote, or on -site monitoring) are provided in the Monitoring Plan.  
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
The Sponsor assumes accountability for actions  delegated to other individuals (eg,  Contract 
Research Organizations).  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by the investigator until at least 2 years after the last approval of a  marketing application 
in an ICH region and until there are no pending  or contemplated marking applications in an ICH 
region or at least 2 -years have elapsed since the formal discontinuation of clinical development 
unless local regulations or  institutional policies r equire a longer retention period. No records may 
be destroyed during the retention period without the written approval of the Sponsor. No records 
may be transferred to another location or party without written notification to the Sponsor.  
10.1.6  Source documents   
Source documentation provides evidence for the existence of the patient and substantiate the 
integrity of the data collected. Source documentation is kept at the Investigator's s ite. 
Data reported on the eCRF or entered in the eCRF that are transcribed from source documentation 
must be consistent with the source documentation or the discrepancies must be explained. The 
Investigator may need to request previous medical records or t ransfer records, depending on the 
study. Also, current medical records must be available.  
Definition of what constitutes source data can be found in Monitoring Plan.  
The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
Study monitors will perform ongoing source data verification to confirm that data entered into the 
eCRF by authorized site personnel are accurate, complete, and verifiable from source 
documentation; that the safety and rights o f patients are being protected; and that the study 
is being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   82 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10.1.7  Study and site start and closure   
10.1.7.1  Trial Stopping Rules   
The trial will be terminated if major safety concerns related to PRN473 or placebo emerge. Trial  
safety stopping criteria are:  
• More than one PRN473 -related death  
• Three or more life -threatening (Common Terminology Criteria for Adverse Events 
[CTCAE], Grade 4) PRN473 -related treatment -emergent adverse events (TEAEs)  
• Sponsor chooses to terminate the study  
10.1.7.2  Study/Site termination   
The Sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the S ponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The Investigator may initiate study -site closu re at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the Sponsor or Investigator may include but are 
not limited to:  
For study termination : 
• Discontinuation of further study intervention development.  
For site termination:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the Sponsor's procedures, or GCP guidelines.  
• Inadequate  or no recruitment (evaluated after a reasonable amount of time) of patients by 
the Investigator.  
• Total number of patients included earlier than expected.  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigat or, the IECs/IRBs, the regulatory authorities, and any Contract Research Organization(s) 
used in the study of the reason for termination or suspension, as specified by the  applicable 
regulatory requirements. The Investigator shall promptly inform the patie nts and  should assure 
appropriate therapy and/or follow -up. 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   83 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10.1.8  Publication policy   
The results of this study may be published or presented at scientific meetings. If this is foreseen , 
the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. 
This allows the Sponsor to protect proprietary information and to provide comments.  
The Sponsor will comply with the requirements for publication of study re sults. In accordance 
with standard editorial and ethical practice, the Sponsor will generally support publication 
of multicenter studies only in their entirety and not as individual site data. In this case, 
a coordinating Investigator will be designated by  mutual agreement.  
Authorship will be determined by mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements.  
10.2 APPENDIX 2: CONTRACEPTIVE AND BARRIER GUIDANCE   
10.2.1  Definition   
A woman is considered WOCBP  (fertile) from the time of menarche until becoming 
postmenopausal (see below) unless permanently sterile (se e below).  
• A postmenopausal state is defined as the period of time after a woman has experienced no 
menses for 12 consecutive months without an alternative medical cause.  
• A high follicle -stimulating hormone (FSH) level in the postmenopausal range may be use d 
to confirm a postmenopausal state in women not using hormonal contraception or 
hormonal replacement therapy (HRT).  
• Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non -estrogen hormonal highly effective contracep tion methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation 
of postmenopausal status before study enrollment.  
Permanent sterilization methods include:  
• Documented hysterectomy  
• Documented bilat eral salpingectomy  
• Documented bilateral oophorectomy  
• For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator 
discretion should be applied to determining study entry eligibility.  
Note: Documentation can come from the site personnel’s review of the patient’s medical records, 
medical examination, or medical history interview.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   84 of 100 
Confidential and Proprietary   01-Mar -2022  Final  If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first administration of study intervention, additional evaluation should be 
considered.  
Women in the following categories are considered WONCBP:  
1. Any female with permanent infertility due to one of the following:  
- Documented hysterectomy  
- Documented bilateral salpingectomy  
- Documented bilateral oophorectomy  
- For individuals with permanent infertility due to an alternate medical cause other than 
the above, (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), 
Investigator discretion should be applied to determining study entry.  
2. Postmenopausal female  
A postmenopausal state is defined as the period of time after a woman has experienced no 
menses for 12 consecutive months wit hout an alternative medical cause.  
- A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using hormonal contraception or 
hormonal replacement therapy (HRT).  
- Females on HRT an d whose menopausal status is in doubt must discontinue HRT to 
allow confirmation of postmenopausal status before study enrollment.  
Note: Documentation can come from the site personnel’s review of the patient’s medical records, 
medical examination, or medic al history interview.  
10.2.2  Contraception guidance   
• If locally required, acceptable contraceptive methods are limited to those which inhibit 
ovulation as the primary mode of action  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   85 of 100 
Confidential and Proprietary   01-Mar -2022  Final  CONT RACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year when used 
consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationc 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)c 
• Bilateral tubal occlusion  
• Azoospermic partner (vasectomized or due to a to medical cause)  
Azoospermia  is a highly effective contraceptive method provided that the partner is the sole sexual partner of 
the woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be us ed. Spermatogenesis cycle is approximately 90 days.  
Note: documentation of azoospermia for a male patient can come from the site personnel’s review of the 
patient’s medical records, medical examination, or medical history interview.  
Highly Effective Metho dsb That Are User Dependent Failure rate of <1% per year when used consistently 
and correctly.  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of  
ovulationc 
- oral 
- intravaginal  
- transdermal  
- injectable  
Progestogen -only hormone contraception associated with inhibition of ovulationc 
- oral 
- injectable  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of 
the patient)  
a Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for those 
participating in clinical studies.  
b Failure rate of <1% per year when used consistently and correctly.  Typical use failure rates differ from  those when used consistently 
and correctly.  
c Male condoms must be used in addition to hormonal contraception . If locally required, in accordance with Clinical Trial 
Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those  which inhibit ovulation as the primary 
mode of action.  
Note: Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides only, and 
lactational amenorrhoea method (LAM) are not acceptable methods of c ontraception. Male condom and female condom should not be 
used together (due to risk of failure with friction)  
 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   86 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10.2.3  Collection of pregnancy information   
Male patients with partners who become pregnant  
• The Investigator will attempt to collect pregnancy information on any male patient’s 
female partner who becomes pregnant while the male patient is in this study. This applies 
only to male patients who receive the IMP.  
• After obtaining th e necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy. The 
female partne r will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the Sponsor. 
Generally, the follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any t ermination of the pregnancy will be reported regardless of fetal status 
(presence or absence of anomalies) or indication for the procedure.  
Female patients who become pregnant  
• The Investigator will collect pregnancy information on any female patient who be comes 
pregnant while participating in this study. The initial information will be recorded on the 
appropriate form and submitted to the Sponsor within 24 hours of learning of a patient's 
pregnancy.  
• The patient will be followed to determine the outcome of the pregnancy. The Investigator 
will collect follow -up information on the patient and the neonate and the information will 
be forwarded to the Sponsor. Generally, follow -up will not be required for longer than 6 to 
8 weeks beyond the estimated delivery dat e. Any termination of pregnancy will be 
reported, regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure.  
• Any pregnancy complication or elective termination of a pregnancy for medical reasons 
will be reported as an AE  or SAE.  
• A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at 
>22 weeks gestational age) is always considered to be an SAE and will be reported as 
such.  
• Any post -study pregnancy related SAE considered reasonably re lated to the study 
intervention by the Investigator will be reported to the Sponsor as described in 
Section  8.3.5 . Whi le the Investigator is not obligated to actively seek this information in 
former study patients, he or she may learn of an SAE through spontaneous reporting.  
• Any female patient who becomes pregnant while participating in the study will 
discontinue study in tervention or be withdrawn from the study.    
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   87 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10.3 APPENDIX 3: LIVER AND OTHER SAFETY: SUGGESTED ACTIONS AND 
FOLLOW UP ASSESSMENTS AND STUDY INTERVENTION RECHALLENGE 
GUIDELINES   
Neutro penia is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting adverse events in Section  8.3.1.3  is met.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   88 of 100 
Confidential and Proprietary   01-Mar -2022  Final   
Thrombocytopenia is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting adverse events in Section  8.3.1.3  is met.  
   
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   89 of 100 
Confidential and Proprietary   01-Mar -2022  Final  *If unable to retest in 72 hours, use original lab results to decide on further reporting/monitoring/discontinuation.  
Note:  
“Base line” refers to ALT sampled at baseline visit; or if baseline value unavailable, to the latest ALT sampled before the baselin e 
visit. The algorithm does not apply to the instances of increase in ALT during screening.  
See Section 8.3 for guidance on safety reporting.   
Normalization is defined as ≤ULN or baseline value , if baseline value is >ULN.  
ALT > 3 ULN
Monitor LFTs every 72 hoursALT ≤ 5 ULN ALT > 3 ULN &
Total Bilirubin > 2 ULN 
Permanent Discontinuation of IMPALT > 5 ULN 
In ANY CASE, FOLLOW the instructions listed in the box below : 
1.INFORM the Site Monitor who will forward the information to the Study Manager
2.INVESTIGATE specifically for malaise with or without loss of consciousness, dizziness, and/or 
hypotension and/or episode of arrhythmia in the previous 72 hours; rule out muscular injury
3.PERFORM the following tests:
-LFTs: AST, ALT, alkaline phosphatase, total and conjugated bilirubin and prothrombin time / INR
-CPK, serum creatinine, complete blood count
-Anti-HAV IgM, anti -HBc IgM, (HBV -DNA if clinically indicated), anti -HCV and HCV RNA, anti -
CMV IgM and anti -HEV IgM antibodies
-Depending on the clinical context, check for recent infection with EBV, herpes viruses, and toxoplasma
-Hepatobiliary ultrasonography (or other imaging investigations if needed)
4.CONSIDER Auto -antibodies: antinuclear, anti -DNA, anti -smooth muscle, anti-LKM
5.CONSIDER consulting with hepatologist
6.CONSIDER patient hospitalisation if INR>2 (or PT<50%) and/or central nervous system disburbances 
suggesting hepatic encephalopathy
7.MONITOR LFTs after discontinuation of IMP:
-As closely as possible (or every 48 hours) until stabilization, then every 2 weeks until return to 
normal/baseline or clinical resolution .
8. FREEZE serum sample (5ml x 2)
9. In case of SUSPICION of GILBERT Syndrome, a DNA diagnostic test should be doneCOMPLETE the specific CRF forms 
for „ALT Increase” and inform the 
Monitoring Team within 24 hours
Confirm ALT > 3 ULN
Retest within 72 hours of initial sample*
IMP administration can be continued as 
long as –under close monitoring –
conditions for permanent 
discontinuation or temporary 
interruption per protocol are not metINCREASE IN ALT
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   90 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10.4 APPENDIX 4: ADDITIONAL APPENDICES   
10.4.1  Grading of application site tolerability symptoms   
 
Grade  Burning/Stinging  Pruritus  Erythema  
0 (none)  No stinging/burning  No pruritus  No detectable erythema; skin 
of normal color  
1 (mild)  Slight warm, tingling 
sensation; not really 
bothersome  Occasional, slight 
itching/scratching  Slight pinkness present  
2 (moderate)  Definite warm, ting ling 
sensation that is somewhat 
bothersome  Constant or intermittent 
itching/scratching that is not 
disturbing sleep  Definite redness, easily 
recognized  
3 (severe)  Hot, tingling/stinging 
sensation that has caused 
definite discomfort  Bothersome itching/scratching 
that is disturbing sleep  Intense redness  
Adapted from: Zane  2016 . 
 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   91 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10.4.2  Validated investigator global assessment -atopic dermatitis (vIGA -AD)  
 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   92 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10.4.3  Lesion Total Sign Score (TSS)   
 
Scale  Erythema  Induration/Papulation  Excoriation  Lichenification  
0 (none)  None  None  None  None  
1  Mild  Mild  Mild  Mild  
2  Moderate  Moderate  Moderate  Moderate  
3  Severe  Severe  Severe  Severe  
  
10.4.4   Hanifin and rajka criteria   
The patient must have 3 of the major criteria and 3 of the minor criteria to be eligible for the 
study.  
 
Major Criteria  
1. Pruritus  
2. Typical morphology and distribution  
 Flexural lichenification in adults  
 Facial and extensor eruptions in infants and children  
3. Chronic or chronically relapsing dermatitis  
4. Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)  
Minor Criteria  
1. Xerosis  
2. Ichthyosis/palmar hyperlinearity, keratosis pilaris  
3. Immediate (type 1) skin -test reactivity  
4. Raised serum IgE  
5. Early  age of onset  
6. Tendency toward cutaneous infections (especially 
Staphylococcus  aureus  and herpes simplex), 
impaired cell -mediated immunity  
7. Tendency toward non -specific hand or foot 
dermatitis  
8. Nipple eczema  
9. Cheilitis  
10. Recurrent conjunctivitis  
11. Dennie -Morgan in fraorbital fold  12. Keratoconus  
13. Anterior subcapsular cataracts  
14. Orbital darkening  
15. Facial pallor, facial erythema  
16. Pityriasis alba  
17. Anterior neck folds  
18. Itch when sweating  
19. Intolerance to wool and lipid solvents  
20. Perifollicular accentuation  
21. Food intolerance  
22. Course in fluenced by environmental or emotional 
factors  
23. White dermographism, delayed blanch  
Source: Hanifin  1980 .  
   
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   93 of 100 
Confidential and Proprietary   01-Mar -2022  Final  10.5 APPENDIX 5: PROTOCOL AMENDMENT HISTORY   
The Protocol Amendment Summary of Changes Table for the current amendment (amended 
protocol 02) is located directly before the Table of Contents.  
Amendment 01 ( 15 June 2021 ) 
This amended protocol 01 (amendment 01) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
This protocol is being amended to incorporate feedback from health authorities as well as other 
clarifications deemed necessary by the Sponsor.  
Protocol amendment summary of changes table  
Section # and Name  Description of Change  Brief Rationale  
Title Page  Updated protocol version and date.  Administrative.  
Protocol amendment summary of changes 
table  Inserted table to include the document 
history related to the initial Clinical 
Study Protocol and the Amended 
Clinical Study Protocol.  
Inserted for the current Amended 
Clinical Study Protocol text related to 
the overall rationale and protoco l 
amendment summary of changes 
table.  New section per Sanofi protocol 
template and process.  
Section 1.1 synopsis; Section 4.1 overall 
design; Section 4.3 justification of dose; 
Section 5.1 inclusion criteria #7; Section 
6.2 
Preparation/handling/storage/accountability  Updated the investigational skin 
lesion from “10*10 cm” to “100cm2” To provide flexibility for the lesional 
area.  
Section 1.1 synopsis; Section 1.2 schema; 
Section 4.1 overall design; Section 5.1 
inclusion crite ria #5,#6; Section 6.7.3 
rescue medicine  Added “genital” in the excluded 
treatable areas for PRN473 Gel 
administration.  To respond the FDA’s comment of 
considering exclusion of  mucosal 
sites such as the genitalia.  
Section 1.1 synopsis; Section 1.2 schema ; 
Section 4.1 overall design  Added the following text to clarify the 
administration of study intervention 
during Open Label period “…and 
should continue to treat the assigned 
areas throughout the Open Label 
Period.”  For clarity.   
Section 1.1 synopsis, Se ction 4.1 overall 
design  Updated the text from”  To evaluate 
the PK (plasma concentrations) and 
biomarkers of PRN473, blood 
samples will be collected throughout 
the study” to “…will be collected at For cla rity. 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   94 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Section # and Name  Description of Change  Brief Rationale  
study visits accordingly to the SoA 
(Section 1.3).”  
Section 1.1 synopsis; Section 5.1 inclusion 
criteria  Replaced the eligibility regarding 
patient’s vIGA -AD score at 
“screening” instead of “baseline “in 
inclusion #5  To correct a typo.  
 Introduced a new inclusion criterion 
as “inclusion #8” for male 
contraception/abstinence 
requirements. And renumbered the 
following inclusion criteria.  To introduce the male 
contraception/abstinence requirements 
in patient eligibility  
 Updated the inclus ion #9 with Sanofi 
common text language on female 
contraception/abstinence and 
pregnancy testing requirements 
following decision tree.  To align with Sanofi common text and 
safety guidance.  
Section 1.1 synopsis; Section 5.2 exclusion 
criteria  Updated the exclusion #17 of any 
malignancy history to “History of any 
malignancy except skin basal cell or 
squamous cell carcinomas in situ that 
have been removed and completely 
resolved at least 5 years ago”  To respond the FDA’s comment.  
 Introduced a new exclusion criterion 
for laboratory abnormalities as 
exclusion #18  To align with Sanofi common text and 
safety guidance.  
 Introduced a new exclusion criterion 
for QT intervals as exclusion #19  To align with Sanofi common text and 
safety guidance. To respond the FDA’s 
comment to add subject stopping 
criteria based on ECG abnormalities.  
 Introduced the diagnostic 
assessments for HIV HBV and HCV 
as exclusion #20, #21, and #22 
respectively.  To align with Sanofi common text and 
safety guidance. To respon d the FDA’s 
comment to obtain HIV test prior to 
study enrollment.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   95 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Section # and Name  Description of Change  Brief Rationale  
 Added the exclusion #23 on medical 
condition of tuberculosis as “Evidence 
of active or latent tuberculosis (TB) as 
documented by medical history and 
examination, chest X -rays (posterior 
anterior and lateral), and TB testing: 
either a positive tuberculin skin test 
(TST; defined as a skin induration ≥ 5 
mm at 48 to 72 hours, regardless of 
Bacillus Calmette -Guerin (BCG) or 
other vaccination history) or a positive 
(not indeterminate) TB test such as 
QuantiFERON® -TB Gold Plus test. 
NOTE: The choice to perform a TST 
or a QuantiFERON -TB Gold Plus test 
will be made by the investigator 
according to local licensing and 
standard of care. The QuantiFERON -
TB Gold Plus test can only be used in 
countries  where it is licensed, and the 
use of this test is dependent on 
previous treatment(s). This test may 
not be suitable if previous 
treatment(s) produced significant 
immunosuppression”  To align with Sanofi common text and 
safety guidance. To respond the FDA’s  
comment to obtain Mantoux TST test 
prior to study enrollment.  
 Introduced the history of serious 
infection or currently active infection 
(including COVID -19) as 
exclusion  #24 To align with Sanofi common text and 
safety guidance.  
 Introduced the receipt of COVID -19 
vaccine as exclusion #25  To align with COVID -19 vaccine safety 
profile.   
Section 1.3 SoA  Updated the assessment item from 
“Evaluation of BSA involvement” to 
“Evaluation of treatable BSA”  For clarity.  
 Added FSH test and footnote f to 
clarify  it is for post -menopausal 
women of non -childbearing potential 
only. Renumbered the footnote 
thereafter.  To align with Table 6.  
 Added Urinalysis test.  To align with inclusion #10 and Table 6  
 Removed the footnote b from PP -
NRS assessment  To correct an error and be consistent 
within protocol.  
 Day 15 has been included in footnote 
q of biomarker collection.  To correct an omission  
 Revised the footnote i with “The vIGA -
AD will be conducted on all treated 
lesions at screening and Day 15, 2 9 
and 43 during Open Label period.  To clarify the vIGA -AD is for all treated 
lesions and the scheduled study visit.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   96 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Section # and Name  Description of Change  Brief Rationale  
 Added “predose at Day 15” at the end 
of footnote j .  To correct an omission.  
 Newly added footnote k “The lesional 
vIGA -AD will be administered predose 
separately on each of the 2 target 
lesions only during Blinded Period 
and predose at Day 15” and crossed 
link to Lesional vIGA assessment. 
Renumber the footnote thereafter.  To clari fy the lesional vIGA -AD is only 
for 2 target lesions and the scheduled 
study visit.  
Section 1.3 SoA, Section 8.9 lesion 
photography  Added “to document biopsy location 
and” for the purpose of photograph in 
footnote j and section 8.9.  For clarity.   
Sectio n 1.3 SoA, Table 6  Introduced the diagnostic 
assessments for Serology (HIV, 
hepatitis B and C) and TB test in 
screening visit.  To align with Sanofi common text and 
safety guidance. To respond the FDA’s 
comment to obtain HIV test prior to 
study enrollment.  
Section 4.1 overall design  Added the text clarifying study 
duration.  For clarity and align with synopsis.  
Section 4.3 justification for dose  Added the following text “Patients will 
measure the dose by the fingertip unit 
method and the expected dose 
variability when the compound is 
topically self -applied by this method 
may be up to two -fold excess of 
compound which is reasonably below 
the safety margin.”  To introduce the guidance for patient 
self-administration of study intervention 
in open -label peri od.  
Section 4.4 end of study definition  Updated the definition for patient 
completed the study to “A patient is 
considered to have completed the 
study if he/she has completed all 
phases of the study including the Day 
43 and Day 56 safety follow up phone  
call.”  For clarity.  
Section 6.7.1 COVID -19 vaccination  Introduced a new section for the 
guidance and requirements of use 
COVID -19 vaccination.  To clarify the guidance of COVID -19 
vaccination during study in the context 
of its approval.   
Section 6.7.2 prohibited medications, 
Table  5 Added any live vaccines in excluded 
medications and treatments list.  To align with vaccine safety profile.   
Section 6.7.4 rescue medicine  Updated the text to “Rescue topical 
medications use will be at the 
discretion of the  Investigator after 
discussion with the Medical Monitor if 
the patient is flaring above 14% 
treatable BSA ( excluding scalp, 
palms, soles and genitalia) during the 
last two weeks of the Open Label 
Period. Investigators should make 
every attempt to conduct efficacy and 
safety assessments (eg, disease To respond the FDA’s comment to 
provide a plan for patients who flare 
and have >14% treatable BSA during 
the open label period.  
 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   97 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Section # and Name  Description of Change  Brief Rationale  
severity scores, safety labs) 
immediately before administering any 
rescue treatment. An unscheduled 
visit may be used for this, if 
necessary. Patients who receive 
rescue treatment will be asked to 
continue with study treatment and 
procedures.”  
Section 7.1 discontinuation of the study 
intervention  Section has been updated to include 
subject stopping criteria based on 
liver chemistry and ECG 
abnormalities. In addition, introduced 
a new sub -section 7.1.4 for 
hematology stopping criteria.  To align with Sanofi common text and 
safety guidance.  
Section 8.2.3 electrocardiograms  Added the following text “ Refer to 
Section 7.1.3 for QTc withdrawal 
criteria and any additional QTc 
readings that may be necessary.”  For clarity. To respond the FDA’s 
comment to add subject stopping 
criteria based on ECG abnormali ties. 
Section 8.2.4.1 clinical laboratory tests 
Table 6  Corrected the clinical chemistry 
assessment from “Urate/Urea” to 
“Blood urea nitrogen (BUN)”  For clarity.  
 Added “Details of liver chemistry 
stopping criteria and required actions 
and follow -up are  given in Section 
7.1.2 Liver Chemistry Stopping 
Criteria and Appendix 5 Liver and 
other safety: suggested actions and 
follow -up assessments. All events 
which may indicate severe liver injury 
(possible Hy’s Law) must be reported 
to Sponsor in an expedited manner 
(excluding studies of hepatic 
impairment or cirrhosis).” as footnote 
a and renumbered the following 
footnotes.  To align with Sanofi common text and 
safety guidance. To respond the FDA’s 
comment to add subject stopping 
criteria based on liver chemist ry. 
Section 8.2.5 Pregnancy testing; Section 
8.3.6 Pregnancy  Whole section been updated.  To align with Sanofi common text and 
safety guidance.  
Section 8.3.5 Regulatory reporting 
requirements for SAEs  Included the regulatory requirement of 
reporting SUS AR as one of the listed 
bullet points.  To align with Sanofi common text and 
safety guidance.  
Section 8.3.7 Expedited reporting 
requirements   Added the time window for expedited 
reporting of AE.  To align with Sanofi common text and 
safety guidance.  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   98 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Section # and Name  Description of Change  Brief Rationale  
Section 9.4.3 analysis of efficacy data  Included the following text “Where 
appropriate, supplemental analyses 
will be presented excluding 
observations after administration of 
rescue medication. Imputation would 
then be performed for missing 
observations in cluding those due to 
withdrawal due to lack of efficacy, as 
will be specified in the SAP.”  To include efficacy data after the use of 
rescue medication.  
Section 9.4.4 analysis of safety data  Included the following text “Where 
appropriate, supplemental ana lyses 
will be presented excluding 
observations after administration of 
rescue medication.”  To include safety data after the use of 
rescue medication.  
Section 10 supporting documentation and 
operational considerations  Added a new subsection 10.1.7.1 for 
trial stopping rules in Appendix 1  To align with Sanofi common text and 
safety guidance.  
 Included the contraceptive and barrier 
guidance, laboratory decision trees for 
neutropenia and thrombocytopenia as 
Appendix 2.  To align with Sanofi common text and 
safety guidance.  
 Included neutropenia and 
thrombocytopenia decision trees in 
Appendix 3  To align with Sanofi common text and 
safety guidance.  
 Grouped the original appendices 1 to 
4 as the subsection of Appendix 4 of 
additional appendices.  For clarity.  
 Protocol amendment history added as 
Appendix 5 per Sanofi template.  Administrative update.  
Throughout document  Replaced “study drug” with “study 
intervention”.  To align with Sanofi protocol template 
terminology recommendation.   
Throughout document  Other minor editorial changes 
(eg, grammatical, stylistic, and minor 
typographical error corrections)  Minor, therefore, have not been 
summarized  
 
  
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   99 of 100 
Confidential and Proprietary   01-Mar -2022  Final  11 REFERENCES   
Ahmed A, Solman L,  Williams HC. Magnitude of benefit for topical crisaborole in the treatment 
of atopic dermatitis in children and adults does not look promising: a critical appraisal. Brit J 
Dermatol . 2018;178:659 -62. 
Bieber T. Atopic dermatitis. Ann Dermatol.  2010;22(2):125 -37. 
Bieber T, D'Erme AM, Akdis CA, Traidl -Hoffmann C, Lauener R, Schäppi G, et al. Clinical 
phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J 
Allergy Clin Immunol . 2017;139(4S):S58 -S64. 
Boguniewicz M, Alexis AF, Beck LA, Block J, Eichenfield LF, Fonacier L, et al. Expert 
Perspectives on Management of Moderate -to-Severe Atopic Dermatitis: A Multidisciplinary 
Consensus Addressing Current and Emerging Therapies. J Allergy Clin Immunol Pract . 
2017;5(6):1519 -31. 
Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune 
dysregulation. Immunol Rev . 2011;242(1):233 -46. 
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with 
Ibrutinib in  Relapsed Chronic Lymphocytic Leukemia. N Engl J Med . 2013;369:32 -42. 
Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, et al. The Bruton tyrosine 
kinase inhibitor PCI -32765 ameliorates autoimmune arthritis by inhibition of multiple effector  
cells. Arthritis Res Ther . 2011;13:R115.  
Crofford  LJ, Nyhoff  LE, Sheehan  JH, Kendall  PL. The role of Bruton’s tyrosine kinase in 
autoimmunity and implications for therapy. Expert Rev Clin Immunol.  2016;12(7):763 -73. 
Di Paolo JA, Huang T, Balazs M, Barbosa  J, Barck KH, Bravo BJ, et al. Specific Btk inhibition 
suppresses B cell - and myeloid cell -mediated arthritis. Nat Chem Biol . 2011;7:41 -50.  
Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of 
care for the manageme nt of atopic dermatitis: section 2. Management and treatment of atopic 
dermatitis with topical therapies. J Am Acad Dermatol . 2014;71(1):116 -32. 
Futatani T, Watanabe C, Baba Y, Tsukada S, Ochs HD. Brutons tyrosine kinase is present 
in normal platelets and its absence identifies patients with X -linked agammaglobulinaemia 
and carrier females. Br J Hematol . 2001;114(1):141 -9. 
Hanifin JM, Rajka G. Diag nostic features of atopic dermatitis. Acta Derm Venereol Suppl 
(Stockh) . 1980;92:44 -7. 
VV-CLIN-0613618 3.0
Product Name: PRN473 (SAR444727)  Clinical Study Protocol PRN473 -0005 (ACT17131)  
Principia Biopharma, Inc.   100 of 100 
Confidential and Proprietary   01-Mar -2022  Final  Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine 
kinase inhibitor PCI -32765 blocks B cell activation and is efficacious in mod els of autoimmune 
disease and B cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075 -80. 
Hutcheson J, Vanarsa K, Bashmakov A, Grewal S, Sajitharan D, Chang BY, et al. Modulating 
proximal cell signaling by targeting Btk ameliorates humoral autoimmunity a nd endorgan disease 
in murine lupus. Arthritis Res Ther.  2012;14:R243.  
Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, et al. Imidazo[1,5 -
a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis. Bioorg 
Med Chem  Lett. 2011;21(21):6258 -63.  
Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, et al. Bruton's tyrosine kinase 
(Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol 
Rev. 2009;228:58 -73. 
Oliveira S,  Rosows ki EE,  Huttenlocher A.  Neutrophil migration in infection and wound repair: 
going forward in reverse. Nat Rev Immunol.  2016;16(6):378 -91.  
Rip J, Van der Ploeg EK, Hendriks RW, Corneth O. The role of Bruton’s Tyrosine Kinase in 
immune cell signaling and sys temic autoimmunity. Crit Rev Immunol . 2018;38(1):17 -62. 
Silverberg JI. Public Health Burden and Epidemiology of Atopic Dermatitis. Dermatol Clin . 
2017;35(3):283 -9. 
Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman -Yassky E, et al. Cellular 
and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin 
Immunol . 2016;138(2):336 -49. 
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis 
Primers . 2018;4(1):1.  
Xu D, Kim Y, Postelne k J, Vu MD, Hu DQ, Liao C, et al. RN486, a selective Bruton's tyrosine 
kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents . 
J Pharmacol Exp Ther . 2012;341:90 -103. 
Zane LT, Hughes MH, Shakib S. Tolerability of crisaborole ointment for application on sensitive 
skin areas: A randomized, double -blind, vehicle -controlled study in healthy volunteers. Am J Clin 
Dermatol . 2016;17:519 -26. 
 
 
VV-CLIN-0613618 3.0